WO2022138707A1 - 筋萎縮性側索硬化症の治療用医薬組成物 - Google Patents
筋萎縮性側索硬化症の治療用医薬組成物 Download PDFInfo
- Publication number
- WO2022138707A1 WO2022138707A1 PCT/JP2021/047532 JP2021047532W WO2022138707A1 WO 2022138707 A1 WO2022138707 A1 WO 2022138707A1 JP 2021047532 W JP2021047532 W JP 2021047532W WO 2022138707 A1 WO2022138707 A1 WO 2022138707A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- epha4
- seq
- amino acid
- pharmaceutical composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 71
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title claims abstract description 44
- 108010055179 EphA4 Receptor Proteins 0.000 claims abstract description 199
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 101
- 230000027455 binding Effects 0.000 claims abstract description 89
- 238000009739 binding Methods 0.000 claims abstract description 79
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 25
- 230000007017 scission Effects 0.000 claims abstract description 22
- 102000021727 EphA4 Receptor Human genes 0.000 claims abstract 6
- 241000282414 Homo sapiens Species 0.000 claims description 213
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 18
- 239000004472 Lysine Substances 0.000 claims description 17
- 210000004899 c-terminal region Anatomy 0.000 claims description 14
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 14
- 102000012803 ephrin Human genes 0.000 claims description 7
- 108060002566 ephrin Proteins 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 abstract description 14
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 description 200
- 241000699666 Mus <mouse, genus> Species 0.000 description 107
- 210000004027 cell Anatomy 0.000 description 101
- 108090000623 proteins and genes Proteins 0.000 description 83
- 102000004169 proteins and genes Human genes 0.000 description 73
- 235000018102 proteins Nutrition 0.000 description 57
- 241000700159 Rattus Species 0.000 description 49
- 239000000243 solution Substances 0.000 description 48
- 238000005406 washing Methods 0.000 description 48
- 239000003446 ligand Substances 0.000 description 45
- 210000004295 hippocampal neuron Anatomy 0.000 description 41
- 102000050554 Eph Family Receptors Human genes 0.000 description 40
- 108091008815 Eph receptors Proteins 0.000 description 40
- 239000013598 vector Substances 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 35
- 108091028043 Nucleic acid sequence Proteins 0.000 description 34
- 229940024606 amino acid Drugs 0.000 description 34
- 150000001413 amino acids Chemical class 0.000 description 33
- 238000000034 method Methods 0.000 description 33
- 239000000126 substance Substances 0.000 description 30
- 150000007523 nucleic acids Chemical class 0.000 description 29
- 108010076504 Protein Sorting Signals Proteins 0.000 description 27
- 239000013604 expression vector Substances 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 23
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 22
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 21
- 241000282693 Cercopithecidae Species 0.000 description 20
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 20
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 20
- 102000039446 nucleic acids Human genes 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 19
- 210000002161 motor neuron Anatomy 0.000 description 19
- 102000002090 Fibronectin type III Human genes 0.000 description 18
- 108050009401 Fibronectin type III Proteins 0.000 description 18
- 108020001756 ligand binding domains Proteins 0.000 description 18
- 239000002609 medium Substances 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- -1 serine (Ser) Chemical class 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 13
- 229920001213 Polysorbate 20 Polymers 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 13
- 239000012228 culture supernatant Substances 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 13
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 13
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 13
- 239000008186 active pharmaceutical agent Substances 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 210000001130 astrocyte Anatomy 0.000 description 12
- 239000006059 cover glass Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 10
- 101000664887 Homo sapiens Superoxide dismutase [Cu-Zn] Proteins 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 102000056070 human SOD1 Human genes 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 108010055196 EphA2 Receptor Proteins 0.000 description 8
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 8
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 8
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000001723 extracellular space Anatomy 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 230000009257 reactivity Effects 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 230000009870 specific binding Effects 0.000 description 8
- 239000012089 stop solution Substances 0.000 description 8
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 7
- 241000283074 Equus asinus Species 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 108010055191 EphA3 Receptor Proteins 0.000 description 6
- 108010055182 EphA5 Receptor Proteins 0.000 description 6
- 108010055207 EphA6 Receptor Proteins 0.000 description 6
- 108010055153 EphA7 Receptor Proteins 0.000 description 6
- 108010055155 EphA8 Receptor Proteins 0.000 description 6
- 108010055334 EphB2 Receptor Proteins 0.000 description 6
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 6
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 6
- 102100021605 Ephrin type-A receptor 5 Human genes 0.000 description 6
- 102100021606 Ephrin type-A receptor 7 Human genes 0.000 description 6
- 102100021601 Ephrin type-A receptor 8 Human genes 0.000 description 6
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 description 6
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 6
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 6
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 6
- 102100031984 Ephrin type-B receptor 6 Human genes 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 101000938354 Homo sapiens Ephrin type-A receptor 1 Proteins 0.000 description 6
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 description 6
- 101001064458 Homo sapiens Ephrin type-B receptor 3 Proteins 0.000 description 6
- 101001064451 Homo sapiens Ephrin type-B receptor 6 Proteins 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 102000016911 Deoxyribonucleases Human genes 0.000 description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 239000012741 Laemmli sample buffer Substances 0.000 description 4
- 239000012722 SDS sample buffer Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000003540 gamma secretase inhibitor Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 239000012881 co-culture medium Substances 0.000 description 3
- 210000001787 dendrite Anatomy 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical group CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102100025698 Cytosolic carboxypeptidase 4 Human genes 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 101800001224 Disintegrin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 238000009004 PCR Kit Methods 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 108010076089 accutase Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical class NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- KQMBIBBJWXGSEI-ROLXFIACSA-N (2s)-2-amino-3-hydroxy-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)C(O)C1=CNC=N1 KQMBIBBJWXGSEI-ROLXFIACSA-N 0.000 description 1
- AJFGLTPLWPTALJ-SSDOTTSWSA-N (2s)-2-azaniumyl-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound FC[C@@](N)(C(O)=O)CC1=CN=CN1 AJFGLTPLWPTALJ-SSDOTTSWSA-N 0.000 description 1
- UYEGXSNFZXWSDV-BYPYZUCNSA-N (2s)-3-(2-amino-1h-imidazol-5-yl)-2-azaniumylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CNC(N)=N1 UYEGXSNFZXWSDV-BYPYZUCNSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000932590 Homo sapiens Cytosolic carboxypeptidase 4 Proteins 0.000 description 1
- 101001037143 Homo sapiens Immunoglobulin heavy variable 3-33 Proteins 0.000 description 1
- 101001138125 Homo sapiens Immunoglobulin kappa variable 1-17 Proteins 0.000 description 1
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 1
- 241000243251 Hydra Species 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 102100040236 Immunoglobulin heavy variable 3-33 Human genes 0.000 description 1
- 102100020945 Immunoglobulin kappa variable 1-17 Human genes 0.000 description 1
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical class CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 102220490832 Mannosyl-oligosaccharide glucosidase_Y32F_mutation Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101001033003 Mus musculus Granzyme F Proteins 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108700013394 SOD1 G93A Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000004009 axon guidance Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000005861 gene abnormality Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 238000012004 kinetic exclusion assay Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000002821 scintillation proximity assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 101150062190 sod1 gene Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000005469 synchrotron radiation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present disclosure relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis (ALS), which comprises an antibody that binds to EphA4.
- ALS amyotrophic lateral sclerosis
- EphA4 is one of the receptor tyrosine kinase families. Ephrin type A and type B are known as ligands for EphA4, and when EphA4 and its ligand, ephrin, bind to each other, a deadhesion signal is induced. EphA4 is expressed in motor neurons, and accurate axon guidance is controlled by the expression of ephrin in the non-projection region of motor neurons in the spinal cord during neural circuit formation. EphA4 is known to be cleaved by matrix metalloproteinase (MMP), ADAM (a disintegrin and metalloproteinase) and ⁇ -secretase in a neural activity-dependent manner.
- MMP matrix metalloproteinase
- ADAM a disintegrin and metalloproteinase
- ALS amyotrophic lateral sclerosis
- neurodegenerative diseases such as Alzheimer's disease, and spinal cord injury. It is suggested that.
- EphA4 is a gene that regulates the phenotype of ALS (Patent Document 1, Non-Patent Document 1). It has been shown that genetic deficiency of EphA4 and antagonism due to EphA4-Fc and the like promote axonal elongation and functional recovery during spinal cord injury in mice and rats (Non-Patent Documents 2 and 3).
- KYL peptide and compound 1 are known as existing EphA4 inhibitors (Patent Document 1, Non-Patent Document 1 and Non-Patent Document 2).
- Antibodies having an activity of inhibiting the binding of EphA4 and its ligand are also known (Patent Documents 2 and 3), but no antibody having an activity of promoting cleavage of EphA4 has been reported so far.
- the present disclosure is intended to provide a novel pharmaceutical composition for treating ALS.
- the present inventors have obtained an antibody effective for the treatment of ALS, which can bind to EphA4 and promote cleavage of EphA4.
- the anti-EphA4 antibody is (A) Heavy chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 44; (B) Heavy chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 27; and (c) Heavy chain containing heavy chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 28; and (d) Heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 29.
- Light chain CDR1 (E) A light chain comprising a light chain CDR2 consisting of the amino acid sequence set forth in SEQ ID NO: 30; and (f) a light chain comprising a light chain CDR3 consisting of the amino acid sequence set forth in SEQ ID NO: 31.
- Pharmaceutical composition comprising a light chain CDR1; (E) A light chain comprising a light chain CDR2 consisting of the amino acid sequence set forth in SEQ ID NO: 30; and (f) a light chain comprising a light chain CDR3 consisting of the amino acid sequence set forth in SEQ ID NO: 31.
- the pharmaceutical composition according to (1) or (2) The anti-EphA4 antibody specifically binds to EphA4 and promotes cleavage of EphA4. Pharmaceutical composition.
- the pharmaceutical composition according to any one of (1) to (3).
- the anti-EphA4 antibody specifically binds to EphA4 and inhibits the binding between EphA4 and ephrin.
- Pharmaceutical composition (4) The pharmaceutical composition according to any one of (1) to (3).
- the anti-EphA4 antibody specifically binds to EphA4 and inhibits the binding between EphA4 and ephrin.
- the heavy chain contains a variable region consisting of the amino acid sequence shown in SEQ ID NO: 45.
- the light chain comprises a variable region consisting of the amino acid sequence set forth in SEQ ID NO: 46.
- the pharmaceutical composition according to any one of (1) to (5) The constant region of the heavy chain and the constant region of the light chain contain an amino acid sequence derived from a human antibody.
- Pharmaceutical composition .
- the pharmaceutical composition according to (6) The constant region of the heavy chain is the constant region of human IgG, Pharmaceutical composition.
- the pharmaceutical composition according to (7) The constant region of human IgG 2 is a constant region of human IgG 2.
- the pharmaceutical composition according to (8) The constant region of human IgG 2 comprises the amino acid sequence set forth in SEQ ID NO: 47.
- the constant region of the light chain is the constant region of human Ig ⁇ .
- the constant region of human Ig ⁇ comprises the amino acid sequence set forth in SEQ ID NO: 48.
- a pharmaceutical composition comprising an anti-EphA4 antibody for treating amyotrophic lateral sclerosis (ALS).
- the anti-EphA4 antibody comprises heavy and light chains.
- the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 59.
- the light chain comprises the amino acid sequence set forth in SEQ ID NO: 60.
- a pharmaceutical composition in which the C-terminal lysine of the heavy chain may be deleted.
- a pharmaceutical composition comprising an anti-EphA4 antibody for treating amyotrophic lateral sclerosis (ALS).
- the anti-EphA4 antibody comprises heavy and light chains.
- the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 59.
- the light chain comprises the amino acid sequence set forth in SEQ ID NO: 60.
- a pharmaceutical composition comprising an anti-EphA4 antibody for treating amyotrophic lateral sclerosis (ALS).
- the anti-EphA4 antibody comprises heavy and light chains.
- the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 59.
- the light chain comprises the amino acid sequence set forth in SEQ ID NO: 60.
- the C-terminal lysine of the heavy chain is deleted, Pharmaceutical composition.
- composition according to any one of (1) to (15). Further comprising at least one pharmaceutically acceptable carrier, Pharmaceutical composition.
- An anti-EphA4 antibody is (A) Heavy chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 44; (B) Heavy chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 27; and (c) Heavy chain containing heavy chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 28; and (d) Heavy chain consisting of the amino acid sequence shown in SEQ ID NO: 29.
- Light chain CDR1 (E) A light chain comprising a light chain CDR2 consisting of the amino acid sequence set forth in SEQ ID NO: 30; and (f) a light chain comprising a light chain CDR3 consisting of the amino acid sequence set forth in SEQ ID NO: 31.
- Anti-EphA4 antibody Anti-EphA4 antibody.
- the anti-EphA4 antibody according to (17) or (18).
- the anti-EphA4 antibody specifically binds to EphA4 and promotes cleavage of EphA4.
- Anti-EphA4 antibody specifically binds to EphA4 and promotes cleavage of EphA4.
- the anti-EphA4 antibody according to any one of (17) to (19).
- the anti-EphA4 antibody specifically binds to EphA4 and inhibits the binding between EphA4 and ephrin.
- Anti-EphA4 antibody specifically binds to EphA4 and inhibits the binding between EphA4 and ephrin.
- the anti-EphA4 antibody according to any one of (17) to (20).
- the heavy chain contains a variable region consisting of the amino acid sequence shown in SEQ ID NO: 45.
- the light chain comprises a variable region consisting of the amino acid sequence set forth in SEQ ID NO: 46.
- Anti-EphA4 antibody is an antigen specific antibody.
- the anti-EphA4 antibody according to any one of (17) to (21).
- the constant region of the heavy chain and the constant region of the light chain contain an amino acid sequence derived from a human antibody.
- Anti-EphA4 antibody is an antibody that is derived from a human antibody.
- the anti-EphA4 antibody according to (22) The constant region of the heavy chain is the constant region of human IgG, Anti-EphA4 antibody.
- the anti-EphA4 antibody according to (23).
- the constant region of human IgG 2 is a constant region of human IgG 2.
- the anti-EphA4 antibody according to (24).
- the constant region of human IgG 2 comprises the amino acid sequence set forth in SEQ ID NO: 47.
- Anti-EphA4 antibody is an anti-EphA4 antibody.
- the anti-EphA4 antibody according to any one of (22) to (25).
- the constant region of the light chain is the constant region of human Ig ⁇ .
- the constant region of human Ig ⁇ comprises the amino acid sequence set forth in SEQ ID NO: 48.
- the anti-EphA4 antibody comprises heavy and light chains.
- the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 59.
- the light chain comprises the amino acid sequence set forth in SEQ ID NO: 60.
- An anti-EphA4 antibody in which the C-terminal lysine of the heavy chain may be deleted.
- the anti-EphA4 antibody comprises heavy and light chains.
- the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 59.
- the light chain comprises the amino acid sequence set forth in SEQ ID NO: 60.
- the anti-EphA4 antibody comprises heavy and light chains.
- the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 59.
- the light chain comprises the amino acid sequence set forth in SEQ ID NO: 60.
- the C-terminal lysine of the heavy chain is deleted, Anti-EphA4 antibody.
- ALS amyotrophic lateral sclerosis
- the pharmaceutical composition comprises at least one pharmaceutically acceptable carrier. Use of anti-EphA4 antibody.
- a novel pharmaceutical composition for treating ALS contains an anti-EphA4 antibody as an active ingredient, which can bind to EphA4 and promote cleavage of EphA4.
- FIG. 1 shows the binding affinity of an anti-EphA4 monoclonal antibody (antibody A) for mouse and human EphA4.
- FIG. 2 shows the EphA4 cleavage promoting activity of an anti-EphA4 monoclonal antibody (antibody A) using hippocampal neurons.
- FIG. 3 shows the mouse EphA4-mouse ligand binding inhibitory activity of the anti-EphA4 monoclonal antibody (antibody A).
- FIG. 4 shows the human EphA4-human ligand binding inhibitory activity of the anti-EphA4 monoclonal antibody (antibody A).
- FIG. 5 shows the selectivity of the anti-EphA4 monoclonal antibody (antibody A) for each human Eph receptor.
- FIG. 1 shows the binding affinity of an anti-EphA4 monoclonal antibody (antibody A) for mouse and human EphA4.
- FIG. 2 shows the EphA4 cleavage promoting activity of an anti-E
- FIG. 6 shows the selectivity of the anti-EphA4 monoclonal antibody (antibody A) for each mouse Eph receptor.
- FIG. 7 shows the reactivity of the anti-EphA4 monoclonal antibody (antibody A) with mouse, rat, monkey and human EphA4.
- FIG. 8 shows the reaction of an anti-EphA4 monoclonal antibody (antibody A) to the human EphA4 extracellular region (ECD), ligand binding domain (LBD), fibronectin type III domain 1 (FN1), and fibronectin type III domain 2 (FN2). Show sex.
- FIG. 9 shows the increasing effect of the anti-EphA4 monoclonal antibody (antibody A) on the spine number of hippocampal neurons.
- ECD EphA4 extracellular region
- LBD ligand binding domain
- FN1 fibronectin type III domain 1
- FN2 fibronectin type III domain 2
- FIG. 10A shows the horizontal axis shows the amino acid of EphA4-Ligand Binding Domain (EphA4-LBD), and the vertical axis shows the structural region of the antibody A-Fab.
- the black bits indicate the intersections of the combinations in which the interactions exist.
- FIG. 10B shows the surface structure of EphA4-Ligand Binding Domain (EphA4-LBD).
- the amino acid name and residue number contained in the binding region are shown at the corresponding positions, and the CDRs of the H and L chains of the antibody A-Fab to which the binding region is bound are shown by a ribbon model.
- FIG. 11 shows the affinity of the humanized anti-EphA4 monoclonal antibody (antibody B) for human EphA4.
- FIG. 12 shows the EphA4 cleavage promoting activity of the humanized anti-EphA4 monoclonal antibody (antibody B) in hippocampal neurons.
- FIG. 13 shows the human EphA4-human ligand binding inhibitory activity of the humanized anti-EphA4 monoclonal antibody (antibody B).
- FIG. 14 shows the mouse EphA4-mouse ligand binding inhibitory activity of the humanized anti-EphA4 monoclonal antibody (antibody B).
- FIG. 15 shows the selectivity of the humanized anti-EphA4 monoclonal antibody (antibody B) to the human Eph receptor.
- FIG. 16 shows the selectivity of the humanized anti-EphA4 monoclonal antibody (antibody B) to the mouse Eph receptor.
- FIG. 17 shows the reactivity of humanized anti-EphA4 monoclonal antibody (antibody B) with mouse, rat, monkey and human EphA4.
- FIG. 18 shows for the human EphA4 extracellular region (ECD), ligand binding domain (LBD), fibronectin type III domain 1 (FN1), and fibronectin type III domain 2 (FN2) of the humanized anti-EphA4 monoclonal antibody (antibody B). Shows reactivity.
- FIG. 19 shows the increasing effect of humanized anti-EphA4 monoclonal antibody (antibody B) on the number of spines in hippocampal neurons.
- FIG. 20 shows the human EphA4 cleavage promoting activity in hippocampal neurons of the humanized anti-EphA4 monoclonal antibody (antibody B).
- FIG. 21 shows the increasing effect of humanized anti-EphA4 monoclonal antibody (antibody B) on the number of spines in hippocampal neurons via MMP and ADAM.
- FIG. 22 shows a schematic diagram of the evaluation system carried out in Example 13.
- FIG. 23 shows the effect of humanized anti-EphA4 monoclonal antibody (antibody B) on human iPS cell-derived motor neuron death induced by mutant human SOD1 (G93A) expressing astrocytes.
- the anti-EphA4 antibody according to the present disclosure is an antibody capable of recognizing and binding to EphA4, and as described below, the antibody may be an intact antibody or has a binding affinity with EphA4. As long as it has sex, it may be a synthetic antibody (for example, recombinant antibody, chimeric antibody, humanized antibody, etc.).
- EphA4 can be understood to refer to EphA4 from humans, mice, rats and monkeys. EphA4 derived from humans, mice, rats and monkeys can be obtained from public databases in which sequence information is registered, such as Genbank provided by the US Center for Biological Engineering, and the nucleotide sequence information of EphA4 of closely related animal species.
- sequence information of the EphA4 gene By designing a primer based on the above and cloning from RNA extracted from a desired animal species, it is possible to obtain sequence information of the EphA4 gene.
- sequence information of the EphA4 gene For example, the nucleotide sequence information of EphA4 in humans, mice, rats, and monkeys can be found in Genbank Accession No. It is registered in the database as NM_004438.5, NM_007936.3, NM_001162411.1, NM_00126087.1.1.
- the anti-EphA4 antibody is an antibody that specifically binds to EphA4.
- the term "specific binding” is a term well known to those of skill in the art in the art, and methods for determining specific binding of an antibody or antigen-binding fragment thereof to an antigen or epitope are also well known.
- "specific binding” means that the anti-EphA4 antibody has greater binding affinity, binding activity, faster and / or longer duration than binding to other target molecules. It is then understood that it can bind to EphA4 by an immunological reaction. This does not mean that the antibody that specifically binds to EphA4 does not bind to other target molecules.
- “specific binding” is by an antibody having a KD of at least about 10-7 M, or at least about 10-8 M, or at least about 10-9 M, or less to EphA4. Can be shown. In yet another embodiment, it is understood that "specific binding” binds to EphA4 by an immunological reaction, but not substantially to other family molecules of the Eph receptor.
- the anti-EphA4 antibody is an antibody that binds to the extracellular space of EphA4. In one embodiment, the anti-EphA4 antibody is an antibody that binds to the ligand binding domain (LBD) of the extracellular space of EphA4.
- LBD ligand binding domain
- the anti-EphA4 antibody can specifically bind to EphA4 and promote cleavage of EphA4. In certain embodiments, the anti-EphA4 antibody can specifically bind to EphA4 and promote cleavage of the EphA4 extracellular domain by matrix metalloproteinase (MMP) or ADAM (a disintegrin and metalloproteinase).
- MMP matrix metalloproteinase
- ADAM a disintegrin and metalloproteinase
- the anti-EphA4 antibody can specifically bind to EphA4 and inhibit the binding of EphA4 to its ligand, ephrin.
- the anti-EphA4 antibody can specifically bind to EphA4 to increase the number of spines in hippocampal neurons or stabilize spines in hippocampal neurons.
- the anti-EphA4 antibody can protect motor neurons from cell death caused by SOD1 gene abnormalities.
- the present disclosure includes, in one embodiment, an anti-EphA4 antibody capable of specifically binding to at least one of human EphA4, mouse EphA4, rat EphA4, and monkey EphA4 and inhibiting binding to its ligand. do.
- the present disclosure comprises, in another embodiment, an anti-EphA4 antibody capable of specifically binding to two or more of human EphA4, mouse EphA4, rat EphA4, and monkey EphA4 and inhibiting binding to its ligands. do.
- the present disclosure includes, in yet another embodiment, an anti-EphA4 antibody capable of specifically binding to all of human EphA4, mouse EphA4, rat EphA4, and monkey EphA4 and inhibiting binding to its ligands.
- binding affinities include Biacore® biosensors, KinExA biosensors, scintillation proximity assays, ELISAs, ORIGEN immunoassays (IGEN), flow cytometry, fluorescence quenching, fluorescence transfer, yeast displays, and / or. , May be measured using immunostaining, but is not limited to these.
- the neutralizing activity of the anti-EphA4 antibody against the binding of EphA4 to its ligand may be measured using, but not limited to, Biacore® biosensor, ELISA, and / or flow cytometry.
- the anti-EphA4 antibody according to the present disclosure may be a monoclonal antibody as long as it binds to EphA4.
- the anti-EphA4 antibody according to the present disclosure may be any class such as IgG, IgA or IgM (or a subclass thereof), and is not limited to a specific class.
- Immunoglobulins are classified into different classes by the antibody amino acid sequence of the constant region of the heavy chain (sometimes called the H chain). There are five major immunoglobulin classes: IgA, IgD, IgE, IgG and IgM, some of which are subclasses (isotypes) of, for example, IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 and IgA 2 . ) Can be further subdivided.
- the corresponding heavy chain constant regions of different classes of immunoglobulins are called ⁇ , ⁇ , ⁇ , ⁇ and ⁇ , respectively.
- ⁇ chains and ⁇ chains in the types of light chains (sometimes called L chains) of antibodies.
- the anti-EphA4 antibody according to the present disclosure may be an IgG antibody, for example, an IgG 1 antibody or an IgG 2 antibody. Further, the anti-EphA4 antibody according to the present disclosure may be in the form of a monomer, a dimer or a multimer, as the case may be.
- variable region of the antibody may mean the variable region of the antibody light chain and / or the variable region of the antibody heavy chain
- the constant region of the antibody is the constant region of the antibody light chain and / or the antibody heavy chain. It may mean a constant region.
- the variable regions of the heavy and light chains each consist of four framework regions (FRs) linked by three CDRs, also known as complementarity determining regions. The CDRs in each strand are held in the vicinity by FR and, together with the CDRs in the other strand, contribute to the formation of the antigen binding site of the antibody.
- the technique for determining the CDR is not limited, but for example, (1) an approach based on interspecies sequence variability (for example, Kabat et al, Sequences of Proteins of Immunological Interest, 5th ed., 1991 National Institute). Of Health, Bethesda MD; and (2) an approach based on the crystal structural study of the antigen-antibody complex (Al-lazikani et al., 1997 J. Molec. Biol. 273: 927-948) can be mentioned. These approaches or other approaches may be used in combination.
- a monoclonal antibody may mean an antibody obtained from a substantially homogeneous population of antibodies. That is, the individual antibodies contained in the population are identical except for some naturally occurring mutants that may be present. Monoclonal antibodies are for a single antigenic site and are highly specific. Moreover, in contrast to typical polyclonal antibodies that target different antigens or different epitopes, each monoclonal antibody targets a single epitope of the antigen.
- the modifier "monoclonal" indicates the properties of an antibody obtained from a substantially homogeneous antibody population and should not be construed as limiting as requiring the production of the antibody by a particular method.
- the anti-EphA4 antibody according to the present disclosure may be a mouse antibody, a chimeric antibody or a humanized antibody.
- a chimeric antibody is, for example, an antibody obtained by fusing a variable region of a non-human (eg, mouse or rat) antibody to a constant region of a human antibody, for example, the variable region is derived from a non-human antibody and the constant region is derived from a human antibody. You may point to an antibody that has become.
- the humanized antibody is, for example, an antibody in which a complementarity determining region (CDR (sometimes referred to as a hypervariable region)) of a non-human antibody is introduced into a human antibody, and the CDR is derived from a non-human antibody, for example.
- CDR complementarity determining region
- Other antibody regions may refer to antibodies derived from human antibodies.
- the boundary between the chimeric antibody and the humanized antibody does not necessarily have to be clear, and it may be in a state that can be called both a chimeric antibody and a humanized antibody.
- the antibody region (FR, constant region) derived from a human antibody does not necessarily have to be composed entirely of amino acids derived from a human antibody, and is one as long as it can be normally used in a human subject. Alternatively, it may contain amino acids derived from a plurality of non-human antibodies.
- the CDR is an antibody derived from a rodent antibody, and the other antibody regions are derived from a human antibody.
- the CDR is an antibody derived from a mouse antibody, and the other antibody region is an antibody derived from a human antibody.
- the CDR may contain amino acids from one or more non-rodental antibodies, or amino acids from one or more non-mouse antibodies, with one antibody region other than CDR. Alternatively, it may contain amino acids derived from a plurality of non-human antibodies.
- the “plurality” is not limited to this, but is limited to 2 to 20, or 2 to 15, for example, 14, 13, 12, 11, 10, and 9. , 8, 7, 6, 5, 4, 3, or 2, or within 10%, within 9%, within 8%, within 7%, 6 of the number of amino acids in the amino acid sequence.
- Humanization can be performed using the CDR transplantation method (Kontermann and Dubel, Antibody Engineering, Springer Lab Manual (2001) and Trussita et al., Methods 36: 69-83 (2005), etc.). Known methods (eg Jones et al., Nature 321: 522-525 (1986); Richmann et al., Nature 332: 323-327 (1988); and Verhoeyen et al., Science 239: 1534-1536 (1988). It can also be done by substituting the CDR sequence for the corresponding sequence of the human antibody using).
- variable regions in both light and heavy chains In order to reduce antigenicity, it may be important to choose the use of human variable regions in both light and heavy chains in the production of humanized antibodies.
- sequences of variable regions of rodent antibodies are screened against the entire library of known human FR sequences. The human sequence closest to the rodent sequence is then accepted as the human FR of the humanized antibody.
- Sims et al. J. Immunol. 151: 2296-2308 (1993) and Chothia et al. , J. Mol. Biol. Please refer to 196: 901-917 (1987).
- a particular framework derived from the common sequence of all human antibodies of a particular subgroup of light or heavy chains is used.
- the same framework can be used for several different humanized antibodies. For example, Carter et al. , Proc. Natl. Acad. Set USA 89: 4285-4289 (1992) and Presta et al. , J. Immunol. 151: 2623-2632 (1993).
- humanized antibodies retain high binding affinity for the antigen and other favorable biological properties.
- humanized antibodies are prepared by the step of analyzing the parent sequence and various conceptual humanized products using a three-dimensional model of the parent sequence and the humanized sequence.
- Three-dimensional immunoglobulin models are generally available and are known to those of skill in the art.
- Computer programs are available that illustrate and display promising three-dimensional structures of selected candidate immunoglobulin sequences. By examining these indications, an analysis of the possible role of the residue in the function of the candidate immunoglobulin sequence, i.e., the residue that affects the ability of the candidate immunoglobulin to bind to its antigen. Analysis is possible.
- FR residues are selected from the recipient sequence and the import sequence so that the desired antibody properties, such as increased binding affinity for one or more target antigens (eg, EphA4 or fragments thereof), are achieved. And can be combined.
- the chimeric antibody or humanized antibody exemplified above is appropriately modified (for example, modification of the antibody or to improve the function of the antibody) while retaining the function of the antibody (or to add or improve the function of the antibody).
- Antibodies with partial substitutions, additions and / or deletions in the amino acid sequences of the antibodies are also included in the anti-EphA4 antibodies according to the present disclosure. More specifically, antibodies in which the amino acid sequence of the constant region is modified to modify the effector function of the antibody are also included in the scope of the present disclosure, for example, antibody-dependent cellular cytotoxicity (ADCC) activity and / or antibody-dependent.
- ADCC antibody-dependent cellular cytotoxicity
- valine (Val) at position 234 in Eunumbering of human IgG2 antibody is replaced with alanin (Ala), and glycine (Gly) at position 237 is replaced with alanin (Ala).
- Substituted antibodies and the like are also included in the scope of the present disclosure.
- the present disclosure also discloses bispecific antibodies (Kontermann (2012), mAbs 4, 182-97) having an antibody binding site having a CDR sequence of an anti-EphA4 antibody according to the present disclosure and an antigen binding site that binds to a different antigen. Included in the range of.
- the anti-EphA4 antibody according to the present disclosure may be modified if desired.
- Modifications of anti-EphA4 antibodies include (a) the three-dimensional structure of the amino acid sequence in the modified region, such as a sheet or helix conformation; (b) the charge or hydrophobic state of the molecule at the target site; or (C)
- the modification may be a modification that alters the effect of the modification on the maintenance of the volume of the side chain, or it may be a modification such that these changes are not clearly observed.
- Modification of the anti-EphA4 antibody according to the present disclosure may be achieved by, for example, substitution, deletion, addition or the like of a constituent amino acid residue.
- amino acid is used in its broadest sense and is a natural amino acid such as serine (Ser), aspartin (Asn), valine (Val), leucine (Leu), isoleucine (Ile), alanine (Ala). ), Tyr, glycine (Gly), lysine (Lys), arginine (Arg), histidine (His), aspartic acid (Asp), glutamic acid (Glu), glutamine (Gln), threonine (Thr), cysteine ( It includes not only Cys), methionine (Met), phenylalanine (Phe), tryptophan (Trp), proline (Pro), but also unnatural amino acids such as amino acid variants and derivatives.
- amino acids herein include, for example, L-amino acids; D-amino acids; chemically modified amino acids such as amino acid variants, amino acid derivatives; norleucine, ⁇ -alanine, and the like. It is naturally understood that amino acids such as ornithine, which are not constituents of proteins in vivo; and chemically synthesized compounds having the characteristics of amino acids known to those skilled in the art can be mentioned.
- unnatural amino acids include ⁇ -methyl amino acids ( ⁇ -methylalanine, etc.), D-amino acids (D-aspartic acid, D-glutamic acid, etc.), and histidine-like amino acids (2-amino-histidine, ⁇ -hydroxy-histidine, etc.).
- Homo histidine, ⁇ -fluoromethyl-histidine, ⁇ -methyl-histidine, etc. amino acids with excess methylene in the side chain (“homo” amino acids) and carboxylic acid functional group amino acids in the side chain are replaced with sulfonic acid groups. Examples thereof include amino acids (such as cysteine acid).
- Naturally occurring amino acid residues can be classified into the following groups, for example, based on general side chain properties: (1) Hydrophobicity: Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilicity: Asn, Gln, Cys, Ser, Thr; (3) Acidity: Asp, Glu; (4) Basicity: His, Lys, Arg; (5) Residues affecting chain orientation: Gly, Pro; and (6) Aromatic: Trp, Tyr, Phe.
- Non-conservative substitution of the amino acid sequences constituting the antibody may be performed by exchanging an amino acid belonging to one of these groups with an amino acid belonging to the other group. More conservative substitutions may be made by exchanging amino acids belonging to one of these groups with other amino acids in the same group. Similarly, the amino acid sequence may be deleted or substituted as appropriate.
- the modification of the amino acids constituting the antibody may be, for example, post-translational modification such as glycosylation, acetylation or phosphorylation with sugar.
- the antibody can be glycosylated at a conserved position in its constant region.
- Glycosylation of antibodies is usually either N-linked or O-linked.
- the N-linked type means the binding of the carbohydrate moiety to the side chain of the asparagine residue.
- O-linked glycosylation may be the binding of either N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid (eg, serine or threonine), optionally 5-hydroxyproline or 5-. It may be a bond to hydroxylysine.
- hydroxyamino acid eg, serine or threonine
- 5-hydroxyproline or 5- optionally 5-hydroxyproline or 5-. It may be a bond to hydroxylysine.
- Those skilled in the art can appropriately select the conditions for glycosylation (for example, when glycosylation is performed using a biological method, the type of host cell or cell medium, pH, etc.). ..
- the anti-EphA4 antibody according to the present disclosure may be further modified alone or in combination by other modification methods based on the common general knowledge known to those skilled in the art.
- the anti-EphA4 antibody according to the present disclosure can be produced by a method well known to those skilled in the art.
- the nucleic acid encoding the anti-EphA4 antibody according to the present disclosure may be incorporated into an expression vector, the expression vector may be introduced into a host cell, and the antibody may be produced by culturing the host cell. Therefore, the present disclosure includes a nucleic acid encoding an anti-EphA4 antibody, a vector containing the nucleic acid, a host cell containing the vector, and a method for producing an anti-EphA4 antibody, which comprises a step of culturing the host cell.
- the nucleic acid encoding the anti-EphA4 antibody according to the present disclosure may have a DNA encoding a signal sequence, and may have a DNA encoding a heavy chain variable region and a DNA encoding a light chain variable region at the 5'end. It may have a DNA encoding a signal sequence.
- the signal sequence is an amino acid residue present at the N-terminus of the protein that is required for the secretory protein or integral membrane protein to pass through the lipid bilayer after being synthesized on the ribosome, and in the present disclosure, this is the amino acid residue.
- the sequence is not particularly limited as long as it has a function.
- Examples of the signal sequence that the anti-EphA4 antibody according to the present disclosure may contain include signal sequences derived from humans, mice, rats, rabbits, donkeys, goats, horses, birds, dogs, cats, yeasts and the like.
- a peptide containing the amino acid sequence represented by SEQ ID NO: 12 or 16 can be mentioned as a signal sequence for a heavy chain
- SEQ ID NO: 14 or 18 can be mentioned as a signal sequence for a light chain.
- Peptides containing the represented amino acid sequence can be mentioned. Further, if they are functionally equivalent, one or more (for example, 2, 3, 4 or 5) in the amino acid sequence represented by SEQ ID NO: 12 or 16 and the amino acid sequence represented by SEQ ID NO: 14 or 18). May have amino acid substitutions, additions and / or deletions.
- the anti-EphA4 antibody according to the present disclosure may be isolated or purified according to a method known to those skilled in the art.
- isolated or purified means artificially isolated or purified from its natural state. If the molecule or composition is naturally occurring, it is “isolated” or “purified” when it is altered, removed from its natural environment, or both. be.
- isolation or purification methods include electrophoretic, molecular biological, immunological or chromatographic techniques, specifically ion exchange chromatography, hydrophobic chromatography, reverse phase. HPLC chromatography, isoelectric point electrophoresis, alkali extraction method and the like can be mentioned, but the present invention is not limited thereto.
- the anti-EphA4 antibody comprises the following CDRs: (A) Heavy chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 44; (B) Heavy chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 27; (C) Heavy chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 28; (D) Light chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 29; (E) Light chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 30; and (f) Light chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 31.
- the anti-EphA4 antibody is a humanized antibody or a chimeric antibody, and in a particular embodiment, it is a humanized antibody.
- the anti-EphA4 antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises a variable region consisting of the amino acid sequence set forth in SEQ ID NO: 45, and the light chain is set forth in SEQ ID NO: 46. It contains a variable region consisting of an amino acid sequence.
- the variable region of the heavy chain and / or the variable region of the light chain contains one or more amino acids in the amino acid sequence shown in SEQ ID NO: 45 and / or the amino acid sequence shown in SEQ ID NO: 46. It may contain substituted, added and / or deleted amino acid sequences.
- plality is not limited as long as it retains the binding affinity for EphA4 and promotes cleavage of EphA4, but is limited to 2 to 15 or 2 to 10, for example, 9 or 8. 7, 6, 5, 4, 3 or 2, or within 10% of the number of amino acids in the amino acid sequence, such as within 9%, within 8%, within 7%, within 6%, 5 Within%, within 4%, within 3%, within 2%, or within 1%.
- the heavy chain of anti-EphA4 antibody comprises a constant region of human IgG 2 .
- the constant region of human IgG 2 comprises the amino acid sequence of SEQ ID NO: 47.
- the light chain of the anti-EphA4 antibody comprises a constant region of human Ig ⁇ .
- the constant region of human Ig ⁇ comprises the amino acid sequence of SEQ ID NO: 48.
- the anti-EphA4 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 59 and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 60.
- the anti-EphA4 antibody lacks lysine located at the C-terminus (carboxy-terminus) of the heavy chain.
- the anti-EphA4 antibody in which the heavy chain C-terminal lysine is deleted is the heavy chain C after translation with an anti-EphA4 antibody in which the heavy chain C-terminal lysine is deleted by genetic modification, carboxypeptidase, or the like.
- anti-EphA4 antibodies in which the terminal lysine has been cleaved.
- the anti-EphA4 antibody in which the C-terminal lysine of the heavy chain is deleted includes not only the anti-EphA4 antibody in which the C-terminal lysine is deleted in both heavy chains but also only one heavy chain.
- an anti-EphA4 antibody in which the C-terminal lysine has been deleted is also included.
- the present disclosure relates to an isolated nucleic acid encoding an anti-EphA4 antibody.
- An isolated nucleic acid encoding an anti-EphA4 antibody refers to one or more nucleic acid molecules encoding a heavy and / or light chain of an anti-EphA4 antibody.
- the nucleic acid according to the present disclosure encodes a heavy chain of an anti-EphA4 antibody.
- the nucleic acid according to the present disclosure encodes the light chain of an anti-EphA4 antibody.
- the nucleic acids according to the present disclosure encode heavy and light chains of anti-EphA4 antibodies.
- the nucleic acids according to the present disclosure also include a first nucleic acid molecule encoding the heavy chain of an anti-EphA4 antibody and a second nucleic acid molecule encoding the light chain of an anti-EphA4 antibody.
- the present disclosure relates to a vector comprising an isolated nucleic acid encoding an anti-EphA4 antibody.
- the vector according to the present disclosure refers to one or more vectors containing an isolated nucleic acid encoding an anti-EphA4 antibody.
- the vector according to the present disclosure is a vector containing a nucleic acid encoding a heavy chain of an anti-EphA4 antibody and a nucleic acid encoding a light chain of an anti-EphA4 antibody.
- the vector according to the present disclosure is a vector comprising nucleic acids encoding the heavy and light chains of an anti-EphA4 antibody.
- the vector according to the present disclosure comprises a first vector comprising a nucleic acid encoding a heavy chain of an anti-EphA4 antibody and a second vector comprising a nucleic acid encoding the light chain of an anti-EphA4 antibody. ..
- the vector according to the present disclosure is not particularly limited to these, but may be a plasmid, cosmid, virus, phage or the like.
- a retrovirus, a lentivirus, an adenovirus, an adeno-associated virus, a simple herpesvirus vector and the like are also included in the vector according to the present disclosure.
- the present disclosure also includes a host cell containing the vector according to the present disclosure, and a method for producing an anti-EphA4 antibody, which comprises a step of culturing the host cell.
- the host cells according to the present disclosure are not particularly limited, but may be Escherichia coli cells, monkey COS cells, Chinese hamster ovary (CHO) cells, NS0 cells and the like.
- the method for producing an anti-EphA4 antibody comprises a step of culturing a host cell and a step of recovering the anti-EphA4 antibody secreted from the host cell (or a culture medium of the host cell).
- the anti-EphA4 antibody according to the present disclosure is used for treating ALS. Accordingly, the present disclosure relates to a pharmaceutical composition for treating ALS, comprising the anti-EphA4 antibody according to the present disclosure.
- the present disclosure also comprises a method of treating ALS, comprising administering to a subject suffering from ALS a therapeutically effective amount of an anti-EphA4 antibody in another embodiment.
- the present disclosure also includes, in yet another embodiment, the use of anti-EphA4 antibodies to produce therapeutic agents for ALS.
- the present disclosure also includes, in yet another embodiment, an anti-EphA4 antibody for use in the treatment of ALS.
- the anti-EphA4 antibody according to the present disclosure can be used alone in a therapeutic method or in combination with other drugs or compositions.
- the anti-EphA4 antibody according to the present disclosure may be administered simultaneously with or at different times with another drug.
- Such combination therapies include combination administration (including two or more agents in the same or separate formulations) and separate administration (eg, simultaneously or sequentially).
- the administration of the anti-EphA4 antibody according to the present disclosure may precede or follow the accompanying treatment.
- the subject to which the anti-EphA4 antibody according to the present disclosure is administered is not limited, and for example, the present invention can be used for human or non-human mammals (monkey, mouse, rat, rabbit, cow, horse, goat, etc.). ..
- the method of administration of the anti-EphA4 antibody according to the present disclosure to a subject is not particularly limited, and the health condition of the subject, the degree of disease, and the drug to be used in combination are not particularly limited.
- a person skilled in the art for example, a doctor can appropriately determine the type of the disease.
- the pharmaceutical composition according to the present disclosure contains the anti-EphA4 antibody according to the above disclosure.
- the pharmaceutical composition according to the present disclosure can be produced according to a known method such as, for example, the method described in the Japanese Pharmacopoeia (JP), United States Pharmacopeia (USP) or European Pharmacopoeia (EP).
- JP Japanese Pharmacopoeia
- USP United States Pharmacopeia
- EP European Pharmacopoeia
- the term "comprise” is intended to include the matters described (members, steps, elements or numbers, etc.) unless the context clearly requires a different understanding. It does not preclude the existence of other matters (members, steps, elements or numbers, etc.).
- the term “consist of” includes aspects described by the terms “consist of” and / or “consentally of”.
- neutralizing activity refers to the activity of inhibiting the binding of EphA4 to its ligand, and / or the signaling that EphA4 induces in the human body by the binding of its ligand, or to the cell. It means an activity that inhibits a molecular expression response or a functional change.
- first and second are used to describe various elements, but these elements should not be limited by these terms themselves. These terms are used only to distinguish one element from the other, for example, the first element is referred to as the second element, and similarly, the second element is the first element. Is possible without departing from the scope of the present disclosure.
- the DNA sequence encoding the signal sequence (SEQ ID NO: 4) and extracellular region (SEQ ID NO: 2) of mouse EphA4 was amplified by RT-PCR using total RNA derived from mouse brain, and then SEAP and histidine tags.
- the pENTR1A vector (Invitrogen / LifeTechnologies) having the DNA sequence encoding the above was cloned into the SalI / NotI site.
- the signal sequence of mouse EphA4 and the DNA sequence encoding the extracellular space, SEAP, and histidine tag were transferred to the pcDNA3.1_rfcB vector by the LR reaction of Gateway System (Invitrogen / Life Technologies), and pcDNA3.1-mouse EphA4 cells.
- An extracellular-SEAP-His expression vector was constructed.
- the constructed pcDNA3.1-mouse EphA4 extracellular region-SEAP-His expression vector was transfected into HEK293EBNA cells (Invitrogen / Life Technologies) using TransIT-LT1 (TAKARA). After 6 days of incubation (5% CO 2 , 37 ° C.), culture supernatant was collected. From the collected culture supernatant, mouse EphA4 extracellular space-SEAP-His protein (SEQ ID NO: 3) was purified using a Proteino column (MACHEREY-NAGEL).
- mice 20 ⁇ g of mouse EphA4 extracellular space-SEAP-His protein was mixed with the same amount of TitterMax Gold adjuvant (TitterMax USA) or GERBU adjuvant (GERBU Biotechnik GmbH) and injected subcutaneously into the footpads of Balb / c mice. Then, on days 3, 7, and 10, mouse EphA4 extracellular space-SEAP-His protein was administered in the same manner. At this time, the TitterMax Gold adjuvant (TiterMax USA) was used only on the 10th day, and the GERBU adjuvant (GERBU Biotechnik GmbH) was used on the 3, 7, and 10th days. On day 13, mice were sacrificed and peripheral lymph nodes were harvested to prepare lymph node cells.
- TitterMax Gold adjuvant TitterMax USA
- GERBU adjuvant GERBU Biotechnik GmbH
- GenomeONE-CF Ishihara Sangyo Kaisha, Ltd.
- the prepared lymph node cells and P3U1 myeloma cells were fused at a ratio of 5: 1.
- the fusion cells were cultured in 96-well plastic plates. After 7 days of incubation (5% CO 2 , 37 ° C.), culture supernatant was collected.
- Reactivity to mouse, rat and human EphA4 includes the extracellular region of mouse EphA4, the extracellular region of rat EphA4 (Genbank Accession No. NP_001155883.1) (positions 20-547) or human EphA4 (Genbank Accession No. NP_004429.
- a protein in which the Fc region of human IgG1 and a histidine tag are fused to the extracellular region (positions 20 to 547) (SEQ ID NO: 6) of SEQ ID NO: 5) hereinafter, “mouse EphA4 extracellular region-Fc”, respectively.
- Mouse, rat or human EphA4 extracellular space-Fc-His protein was prepared by the following steps. First, pcDNA3.1-mouse, rat or human EphA4 extracellular region-Fc-His expression vector was constructed. First, the signal sequence of mouse, rat or human EphA4 and the DNA sequence encoding the extracellular region are amplified by RT-PCR using total RNA derived from the brain of mouse, rat or human, and Fc and histidine tags are encoded. It was cloned into the SalI / NotI site of a pENTR1A vector (Invitrogen / Life Technologies) having a DNA sequence.
- pENTR1A vector Invitrogen / Life Technologies
- the signal sequence and extracellular region of mouse, rat or human EphA4 and the DNA sequence encoding the Fc and histidine tags were transferred to the pcDNA3.1_rfcB vector by the LR reaction of Gateway Systems (Invitrogen / Life Technologies), and pcDNA3.1.
- -A mouse, rat or human EphA4 extracellular region-Fc-His expression vector was constructed. These constructed expression vectors were transfected into HEK293EBNA cells (Invitrogen / Life Technologies) using TransIT-LT1 (TAKARA). After 6 days of incubation (5% CO 2 , 37 ° C), culture supernatant was collected.
- ELISA using mouse, rat or human EphA4 extracellular space-Fc-His protein was performed according to the following steps.
- Anti-human IgG antibody Jackson ImmunoResearch Laboratories
- 1x Block Ace (Dainippon Pharmaceutical Co., Ltd.) at room temperature for 1 hour.
- Tween20 / PBS Nacalai Tesque
- culture supernatant containing mouse, rat or human EphA4 extracellular space-Fc-His protein was added to each well (final concentration 1 nM) and brought to room temperature. Incubated for 1 hour.
- Hybridomas were cloned from the wells picked up through the above steps by the limiting dilution method, and finally hybridoma clones expressing mouse anti-EphA4 antibody having binding activity to mouse, rat and human EphA4 were obtained.
- the obtained hybridoma clone was cultured, and a mouse anti-EphA4 monoclonal antibody was purified from the culture supernatant using Protein A (GE Healthcare).
- Rat hippocampal neurons were prepared according to the following steps. The fetus was taken out from a rat (Charles River, Japan) on the 18th day of gestation, and the head was incised to take out the brain.
- digestion solution 137 mM NaCl (Wako Pure Chemical Industries, Ltd.), 5 mM KCl (Wako Pure Chemical Industries, Ltd.), 7 mM Na 2 HPO 4 (Wako Pure Chemical Industries, Ltd.), 25 mM Hepes (DOJINDO), 0.5 mg It was placed in / mL DNase (Sigma), 0.25% trypcin (Life technologies) and shaken at 37 ° C. for 10 minutes. The solution was removed and 20% Fetal bovine serum / Hanks buffer (Sigma) was added.
- EphA4 cleavage promoting activity using hippocampal neurons was performed according to the following steps. Rat hippocampal neurons seeded in 96-weldish (Falcon) were treated with anti-EphA4 monoclonal antibody (67 nM) and ⁇ -secretase inhibitor Compound E (50 nM, Enzo Life Sciences) 16 hours later with PBS (Wako Pure Drug). The cells were collected with SDS sample buffer (Laemmli sample buffer (Bio-Rad), 5% 2-mercaptoethanol (Bio-Rad)), and boiled for 5 minutes. SDS-PAGE was performed using this sample, Western blotting was performed using an anti-EphA4 monoclonal antibody (Abnova), band intensity was quantified, and the value of EphA4C terminal fragment / total length EphA4 was calculated.
- SDS sample buffer Laemmli sample buffer (Bio-Rad)
- 2-mercaptoethanol Bio-Rad
- a mouse anti-EphA4 monoclonal antibody (antibody A) having an activity of promoting cleavage of EphA4 was obtained.
- the isotype of antibody A was determined by a monoclonal antibody isotyping kit (Serotec), which was IgG 1 for heavy chains and ⁇ for light chains.
- the obtained cDNA was used as a 5'forward primer (5'-PCR4 primer, AGCTACGCTGAAGTATCAACGCAGAG) (SEQ ID NO: 9) and a 3'reverse primer (GCCAGTGGATAGACTGATGG (SEQ ID NO: 10) for amplification of mouse IgG heavy chain, and mouse Ig ⁇ light.
- the chain was amplified by GATGGATACAGTTGGTGCAGC (SEQ ID NO: 11).
- the amplified cDNA was inserted into a pCR2.1 vector (Invitrogen / Life Technologies).
- the gene sequence of antibody A was analyzed using ABI3130XL.
- the heavy chain signal sequence is the sequence shown in SEQ ID NO: 12
- the heavy chain variable region is the sequence shown in SEQ ID NO: 13
- the light chain signal is the sequence shown in SEQ ID NO: 14
- the light chain variable region is the sequence shown in SEQ ID NO: 15.
- the heavy chain signal sequence is the sequence shown in SEQ ID NO: 16
- the heavy chain variable region is the sequence shown in SEQ ID NO: 17, and the light chain signal sequence is shown in SEQ ID NO: 18. It is a sequence, and the light chain variable region is the sequence shown in SEQ ID NO: 19.
- RNA was prepared from the hybridoma using RNeasy (QIAGEN) and treated with DNase (QIAGEN, RNase free DNase set).
- a reverse transcriptase was prepared from the total RNA using the RNA PCR kit (TAKARA). Using the obtained reverse transcript as a template, the gene sequence encoding the heavy chain and light chain of antibody A was lightly used with a 5'forward primer (GCGAAGCTTGCCGCCACCATGGCTGTCCTGGTGCTGCTCC (primerID7455) (SEQ ID NO: 20) for amplification of the heavy chain.
- the CDR of antibody A was determined by the following method.
- the amino acid sequence of antibody A was numbered using Abysis software (UCL) according to Kabat's numbering system. Based on this number, it was determined according to the definition of Kabat for identification of CDR (Kabat definition).
- the amino acid sequence of the CDR of antibody A is shown in Table 1.
- Reference Example 2 Binding affinity of anti-EphA4 monoclonal antibody to mouse and human EphA4 The binding affinity of antibody A to mouse and human EphA4 was determined by surface plasmon resonance (SPR method) using Biacore T200 (GE Healthcare).
- SPR method surface plasmon resonance
- an anti-His antibody (GE Healthcare, 28-9950-56) was immobilized on the sensor chip CM5. Immobilization is performed by an amine coupling method using N-hydroxysuccinimide (NHS) and N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), and ethanolamine is used for blocking.
- NHS N-hydroxysuccinimide
- EDC N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride
- ethanolamine is used for blocking.
- binding affinities (KD values) of antibody A to mouse and human EphA4 were 1.32 ⁇ 10-9 M and 1.19 ⁇ 10-9 M, respectively (FIG. 1).
- Other binding parameters for mouse and human EphA4 were similar. Therefore, antibody A is considered to have a similar binding affinity for mouse and human EphA4.
- Reference Example 3 The EphA4 cleavage promoting activity antibody A in the hippocampal neurons of the anti-EphA4 monoclonal antibody was evaluated for the EphA4 cleavage promoting activity using the hippocampal neurons according to the following steps. Rat hippocampal neurons seeded in 96-weldish (Falcon) were treated with antibody A (2.0, 6.7, 20 nM) and the ⁇ -secretase inhibitor CompoundE (50 nM, Enzo Life Sciences) 24 hours later with PBS.
- Falcon Rat hippocampal neurons seeded in 96-weldish (Falcon) were treated with antibody A (2.0, 6.7, 20 nM) and the ⁇ -secretase inhibitor CompoundE (50 nM, Enzo Life Sciences) 24 hours later with PBS.
- the cells were washed with (Wako Junyaku), SDS sample buffer (Laemmli sample buffer (Bio-Rad), 5% 2-mercaptoethanol (Bio-Rad)) was added, and the cells were collected and boiled for 5 minutes. SDS-PAGE was performed using this sample, Western blotting was performed using an anti-EphA4 monoclonal antibody (Abnova), band intensity was quantified, and the value of EphA4C terminal fragment / total length EphA4 was calculated.
- SDS sample buffer Laemmli sample buffer (Bio-Rad)
- 2-mercaptoethanol Bio-Rad
- Antibody A promoted the EphA4 cleavage reaction in hippocampal neurons in a concentration-dependent manner (Fig. 2).
- Reference Example 4 Mouse EphA4-mouse ligand binding inhibitory activity of anti-EphA4 monoclonal antibody
- antibody A the binding inhibitory activity between mouse EphA4 and mouse ligand was evaluated according to the following steps.
- Anti-alkaline phosphatase antibody (Thermo SCIENTIFIC) was coated on wells of 96-well plates (Nunc). After incubating overnight at 4 ° C., wells were blocked at room temperature for 1 hour with 1% Block Ace (DS Pharma Biomedical).
- mouse EphA4 extracellular space-SEAP-His protein was added to the wells (final concentration 10 nM) and incubated for 1 hour at room temperature. After washing 3 times, the wells were loaded with ligand and antibody A (0, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000, 3000 nM) was added.
- biotinylated mouse EphrinA1-Fc chimera R & D Systems, final concentration 6 nM
- biotinylated mouse EphrinB2-Fc chimera R & D Systems, final concentration 2.5 nM
- TMBZ horseradish peroxidase-labeled streptavidin
- TMBZ TMBZ (3,3', 5,5'-tetramethylbenzidine, Sigma) solution was added to the wells, and the mixture was incubated for 2 minutes at room temperature.
- An equal amount of reaction arrest solution (1NH 2 SO 4 , Wako Pure Chemical Industries, Ltd.) was added to the wells, and the absorbance at 450 nm was read with a microplate reader (PerkinElmer).
- Antibody A suppressed the binding between mouse EphA4 and mouse ligand in a concentration-dependent manner, and the IC50 values for mouse EphrinA1 and EphrinB2 binding were about 5.9 nM and 3.1 nM, respectively (FIG. 3). Therefore, it was shown that antibody A strongly inhibits the binding between mouse EphA4 and mouse ligand.
- Reference Example 5 Human EphA4-human ligand binding inhibitory activity of anti-EphA4 monoclonal antibody
- antibody A the binding inhibitory activity between human EphA4 and human ligand was evaluated according to the following steps.
- Anti-alkaline phosphatase antibody (Thermo SCIENTIFIC) was coated on wells of 96-well plates (Nunc). After incubating overnight at 4 ° C., wells were blocked at room temperature for 1 hour with 1% Block Ace (DS Pharma Biomedical).
- human EphA4 extracellular space-SEAP-His protein was added to the wells (final concentration 10 nM) and incubated for 1 hour at room temperature. After washing three times, the wells were serially diluted with ligand A (0, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000, 3000 nM) was added.
- a biotinylated human EphrinA5-Fc chimera (R & D Systems, final concentration 0.7 nM) and a biotinylated human EphrinB3-Fc chimera (R & D Systems, final concentration 2.3 nM) were used.
- horseradish peroxidase-labeled streptavidin (GE Healthcare) was added, and the mixture was incubated at room temperature for 1 hour.
- TMBZ (3,3', 5,5'-tetramethylbenzidine, Sigma) solution was added to the wells, and the mixture was incubated for 2 to 5 minutes at room temperature.
- An equal amount of reaction arrest solution (1NH 2 SO 4 , Wako Pure Chemical Industries, Ltd.) was added to the wells, and the absorbance at 450 nm was read by a microplate reader (Molecular Devices or PerkinElmer).
- Antibody A suppressed the binding between human EphA4 and human ligand in a concentration-dependent manner, and the IC50 values for human EphrinA5 and EphrinB3 binding were about 2.8 nM and 1.4 nM, respectively (FIG. 4). Therefore, it was shown that antibody A also strongly inhibits the binding between human EphA4 and human ligand.
- Reference Example 6 Selectivity of anti-EphA4 monoclonal antibody for human Eph receptor
- each human Eph receptor EphA1, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, EphA8, EphA10, EphB1, EphB2, EphB3, EphB4, EphB6
- signal sequences and DNA sequences encoding extracellular regions are amplified by RT-PCR using tissue-derived Total RNA and SEAP.
- a pENTR1A vector Invitrogen / LifeTechnologies
- each human Eph receptor the DNA sequence encoding the SEAP and histidine tags are transferred to the pcDNA3.1_rfcB vector by the LR reaction of Gateway System (Invitrogen / Life Technologies), and each human Eph receptor is transferred.
- Gateway System Invitrogen / Life Technologies
- each human Eph receptor is transferred.
- a vector that expresses a protein in which SEAP and His tags are fused to the extracellular space of SEAP referred to as "Eph receptor extracellular space-SEAP-His protein" (referred to as "Eph receptor extracellular space-SEAP-His protein expression vector").
- each human Eph receptor extracellular space-SEAP-His protein expression vector was introduced into Expi293F cells (Gibco / Thermo Fisher). After culturing for 5 days (5% CO2, 37 ° C., 120 rpm), the culture supernatant was collected and centrifuged at 1500 rpm for 5 minutes at room temperature. The centrifugation supernatant was filtered through a 0.45 ⁇ m filter (Millipore).
- the binding activity of the human Eph receptor was evaluated according to the following steps. Rabbit anti-6-His antibody (Bethyl Laboratories) was coated on wells of 96-well plates (Nunc). After incubating overnight at 4 ° C., wells were blocked at room temperature for 1 hour with 1% Block Ace (DS Pharma Biomedical). After washing 3 times with 0.05% Tween20 / PBS (Thermo SCIENTIFIC), each well was inoculated with each human Eph receptor extracellular space-SEAP-His protein (final concentration 1 nM) and incubated for 1 hour at room temperature. ..
- Antibody A had a specific binding activity only to human EphA4 among the human Eph receptor families (Fig. 5).
- Reference Example 7 Selectivity of anti-EphA4 monoclonal antibody for mouse Eph receptor
- each Eph receptor in mice (EphA1, EphA3, EphA4, EphA5, EphA6).
- EphA7, EphA8, EphA10, EphB1, EphB2, EphB3, EphB4, EphB6) and the DNA sequence encoding the extracellular space were amplified by RT-PCR using tissue - derived Total RNA to obtain human IgG1.
- mice It was cloned into a pENTR1A vector (Invitrogen / LifeTechnologies) having a DNA sequence encoding an Fc region and a histidine tag.
- EphA1, EphA3, EphA4, EphA5, EphA6, EphA7, EphA8, EphA10, EphB1, EphB2, EphB3, EphB4, EphB6) of mice are encoded.
- the DNA sequence was transferred to the pcDNA3.1_rfcB vector by the LR reaction of Gateway System (Invitrogen / LifeTechnologies) to construct the extracellular space-Fc-His protein expression vector of each Eph receptor in mice.
- Gateway System Invitrogen / LifeTechnologies
- the signal sequence of mouse EphA2 and the DNA sequence encoding the extracellular region were amplified by RT-PCR using tissue-derived Total RNA, and Fc and Fc and A mouse EphA2 extracellular region-Fc-His protein expression vector was constructed by cloning into a pcDNA3.1 vector having a DNA sequence encoding a histidine tag.
- each Eph receptor extracellular space-Fc-His protein expression vector of mice was introduced into Expi293F cells (Gibco / Thermo Fisher). After culturing for 5 days (5% CO2, 37 ° C., 120 rpm), the culture supernatant was collected and centrifuged at 1500 rpm for 5 minutes at room temperature. The centrifugation supernatant was filtered through a 0.45 ⁇ m filter (Millipore).
- the binding activity of the mouse Eph receptor was evaluated according to the following steps. Rabbit anti-6-His antibody (Bethyl Laboratories) was coated on wells of 96-well plates (Nunc). After incubating overnight at 4 ° C., wells were blocked at room temperature for 1 hour with 1% Block Ace (DS Pharma Biomedical). After washing 3 times with 0.05% Tween20 / PBS (Thermo SCIENTIFIC), each well was inoculated with each Eph receptor extracellular space-Fc-His protein (final concentration 1 nM) of mice and incubated at room temperature for 1 hour. ..
- Antibody A had a specific binding activity only to mouse EphA4 among the mouse Eph receptor families (Fig. 6).
- Reference Example 8 Responsiveness of anti-EphA4 monoclonal antibody to mouse, rat, monkey and human EphA4 Mouse, rat, monkey and human EphA4 extracellular region-Fc-His protein was prepared according to the following steps. First, a monkey EphA4 extracellular region-Fc-His protein expression vector was constructed according to the method for preparing the EphA4 extracellular region-Fc-His protein described in Reference Example 1. The amino acid sequence of monkey EphA4 used in vector construction is shown as SEQ ID NO: 32, and its extracellular space is shown as SEQ ID NO: 33.
- Antibody A had the same binding activity in all of mouse, rat, monkey and human EphA4 (Fig. 7).
- pcDNA3.4-human EphA4 extracellular region, ligand binding domain, fibronectin type III domain 1, or fibronectin type III domain 2-MBP-His expression vector was constructed.
- the signal sequence of human EphA4 (SEQ ID NO: 34) or the signal sequence of preprotrypsin (SEQ ID NO: 35) and the DNA sequence encoding each domain of human EphA4 are amplified by PCR, and the DNA sequence encoding MBP and histidine tag is obtained.
- the expression vector was transfected into Expi293F cells (Thermo SCIENTIFIC) using the Expi293 expression system (Thermo SCIENTIFIC). After 4 days, the culture supernatant was collected and passed through a 0.45 ⁇ m filter (Millipore). Rough purification was performed using Amylose resin (NEB), and buffer-substituted with PBS (Wako Pure Chemical Industries, Ltd.) using Zeba Spin Deserting colon (Thermo SCIENTIFIC). The monomer fraction was fractionally purified with Superdex200 10/300 (GE Healthcare).
- antibody A The binding activity of antibody A to various human EphA4 domains was evaluated according to the following steps. Rabbit anti-6-His antibody (Bethyl Laboratories) was coated on wells of 96-well plates (Nunc). After incubating overnight at 4 ° C., wells were blocked at room temperature for 1 hour with 1% Block Ace (DS Pharma Biomedical).
- human EphA4 extracellular region-MBP-His protein, human EphA4 ligand binding domain-MBP-His protein, human EphA4 fibronectin type III domain 1- MBP-His protein and human EphA4 fibronectin type III domain 2-MBP-His protein (final concentration 10 nM) were seeded and incubated at room temperature for 1 hour. After washing 3 times, antibody A (final concentration 10 nM) was added to the wells and incubated at room temperature for 1 hour.
- Horseradish peroxidase-labeled goat anti-mouse IgG Fc ⁇ fragment antibody (Jackson ImmunoResearch Laboratories) was added and incubated for 1 hour at room temperature. After washing 5 times, add TMB solution (KPL) to the wells, and after confirming appropriate color development, add an equal amount of reaction stop solution (2NH 2 SO 4 , Wako Pure Chemical Industries, Ltd.) to the wells, and microplate reader (PerkinElmer). The absorbance at 450 nm and 650 nm was read.
- Antibody A had binding activity to the human EphA4 extracellular space (ECD) and ligand binding domain (LBD) (FIG. 8). It did not react with fibronectin type III domain 1 (FN1) and fibronectin type III domain 2 (FN2). Therefore, it was found that antibody A specifically binds to the ligand-binding domain of the extracellular region of human EphA4.
- Reference Example 10 Increasing effect of anti-EphA4 monoclonal antibody on the number of spines of hippocampal neurons
- Preparation of rat hippocampal neurons was performed as described in (B) of Reference Example 1 above.
- a 24-well plate containing a poly-L-lysine-coated cover glass (Matsunami Glass Ind.) In which the EGFP gene was introduced into rat hippocampal neurons using Nucleofector (Lonza) and mixed with rat hippocampal neurons without gene transfer. It was sown in Falcon).
- Control antibody (mouse IgG 1 ; BioLegend) or antibody A (mouse IgG 1; BioLegend) or antibody A (mouse IgG 1; BioLegend) or antibody A (mouse IgG 1; BioLegend) or antibody A (mouse IgG 1; BioLegend) or antibody A (mouse IgG 1; BioLegend) or antibody A (mouse IgG 1; BioLegend) or antibody A (mouse IgG 1; BioLegend) or antibody A (mouse IgG 1; BioLegend) or antibody A (mouse IgG 1; BioLegend) or antibody A 6.7, 20 nM) was treated for 24 hours.
- the cover glass was transferred to 2% PFA (Wako Pure Chemical Industries, Ltd.) / 4% Sucrose (Wako Pure Chemical Industries, Ltd.) / PBS and allowed to stand for 20 minutes to fix the cells. After removing the fixation solution, the cells were washed 3 times with PBS, 0.25% Triton X-100 (Wako Pure Chemical Industries, Ltd.) / PBS was added, and cell permeation treatment was performed for 15 minutes. Remove the liquid, transfer the cover glass to 2% BSA (Sigma) / 0.25% TritonX-100 / Opti-MEM (GIBCO), block for 1 hour, and then apply anti-GFP antibody (Nacalai Tesque) for 1 hour.
- the reaction was carried out for 30 minutes.
- the primary antibody solution was removed, the cells were washed 3 times with PBS, and then the secondary antibody was reacted for 1 hour.
- Prolong Gold antibody reagent (Molecular probes) was added and encapsulated, and observation was performed with LSM800 (ZEISS).
- the above-mentioned experiments were carried out three times, and neurons were extracted from two cover glasses for each experiment, and the spines on each dendrite were counted using the image analysis software Imaris (registered trademark) (Bitplane). , The number of spines per 10 ⁇ m in each neuron was calculated.
- Antibody A increased the number of spines in hippocampal neurons (Fig. 9). This result indicates that antibody A has the activity of stabilizing spines in hippocampal neurons.
- Reference Example 11 Preparation of the epitope mapping antibody A-Fab of the EphA4-ligand binding domain (EphA4-LBD) by X-ray crystal structure analysis was carried out according to the following steps. 101.1 mg of antibody A was dissolved in 0.1 M sodium phosphate buffer (pH 7.0) containing 30 mM L-cysteine and 2 mM EDTA at a concentration of 15 mg / mL. To this antibody solution, 1/200 amount of papain (Sigma) was added to the antibody, and enzymatic digestion was performed at 37 ° C. for 18 hours.
- papain Sigma
- the antibody A enzyme digestion solution was dialyzed against PBS, and then the precipitate was removed by centrifugation (the resulting precipitate was redissolved in PBS and mixed with the centrifugation supernatant). Next, the following steps were performed for the purpose of removing impurities other than the antibody A-Fab.
- 1) Purification by Protein A column This enzyme digestion solution was applied to 2 mL of ProSep vA High Capacity (Millipore) equilibrated with PBS, and the pass-through fraction and the washed fraction with PBS were collected.
- EphA4-LBD was prepared in order to prepare a complex of the antibody A-Fab and the antigen EphA4-LBD (Qin H. et al., J. Biol. Chem., 283: 29473-29484 (2008)). 0.68 ⁇ mol (200 ⁇ M, 3.4 mL) of EphA4-LBD and 0.45 ⁇ mol (300 ⁇ M, 1.5 mL) so that EphA4-LBD has a molar ratio of about 1.5 times that of antibody A-Fab. The antibody A-Fab was mixed.
- the mixed solution was applied to HILOAD 26/60 Superdex 75 prep grade (GE Healthcare) and eluted with a chromatographic buffer (25 mM Tris / HCl (pH 7.5), 100 mM NaCl). Fractions containing the complex were analyzed by SDS PAGE, high-purity fractions were collected and concentrated to about 40.8 mg / mL, which was used for crystallization.
- a chromatographic buffer 25 mM Tris / HCl (pH 7.5), 100 mM NaCl.
- the crystallization of the complex was carried out by a sitting drop steam diffusion method using an automatic crystallization device Hydra II Plus One system (Matrix Technologies Corp., Ltd.).
- the plate used was MRC-2 (Molecular Dimensions).
- the composition of the reservoir solution is 100 mM HEPES (pH 7.5), 10% Polyethylene Glycol 8000, 8% Ethylene Glycol, and the volume ratio of this reservoir solution and the above complex solution is 1: 1 and crystallization drops. A let was made.
- the prepared crystallization plate was allowed to stand at 20 ° C.
- the crystal structure of the obtained antibody A-Fab / EphA4-LBD complex was analyzed using the interaction detection tool installed in the computational chemistry system MOE 2018.0101 (Chemical Computing Group Inc.), and the antibody A-Fab was analyzed.
- Amino acid residues on EphA4-LBD in direct contact with were identified (FIG. 10A).
- the identified amino acid residues are Glu51, Gly52, Ile59, Gln71, Cys73, Asn74, Val75, Met76, Glu77, Thr104, Arg106, Leu111, Pro112, Met115, Arg162, Met164, Cys191, Ala193, Val195.
- FIG. 10A The identified amino acid residues are Glu51, Gly52, Ile59, Gln71, Cys73, Asn74, Val75, Met76, Glu77, Thr104, Arg106, Leu111, Pro112, Met115, Arg162, Met164, Cys191, Ala193, Val195.
- Example 1 Preparation of a humanized antibody of antibody A
- Preparation of humanized anti-EphA4 antibody A variable region of the humanized antibody was designed. Based on the high homology to the framework region (FR) of antibody A, among the FRs of human antibodies, IGHV3-33 * 03 (SEQ ID NO: 42), JH6 (SEQ ID NO: 43), and light chain for heavy chains. For, IGKV1-17 * 01 (SEQ ID NO: 40) and JK4 (SEQ ID NO: 41) were selected as FRs of humanized antibodies.
- the heavy chain constant region the constant region of human IgG 2 (SEQ ID NO: 47) was used.
- Human Ig ⁇ (SEQ ID NO: 48) was used as the light chain constant region.
- an expression vector (pcDNA3.4) containing a gene sequence encoding the amino acid sequence of a humanized antibody was transfected into Expi293F cells (Gibco / ThermoFiser).
- the gene sequence encoding the amino acid sequence of the humanized antibody the nucleic acid sequence shown in SEQ ID NO: 55 is used for the heavy chain variable region, and the nucleic acid sequence shown in SEQ ID NO: 56 is used for the light chain variable region.
- the nucleic acid sequence shown in SEQ ID NO: 57 was used for the region, and the nucleic acid sequence shown in SEQ ID NO: 58 was used for the light chain constant region.
- the amino acid sequence of the full length of the heavy chain (not including the signal sequence) of the humanized antibody is the amino acid sequence shown in SEQ ID NO: 59, and the amino acid sequence of the full length of the light chain (not including the signal sequence) is the amino acid shown in SEQ ID NO: 60. It is an array.
- the nucleic acid sequence encoding the full length of the heavy chain of the humanized antibody is the nucleic acid sequence shown in SEQ ID NO: 61
- the nucleic acid sequence encoding the full length of the light chain is the nucleic acid sequence shown in SEQ ID NO: 62.
- the supernatant was collected, and the humanized antibody (antibody B) of antibody A was purified using MabSelectSuRe (GE Healthcare).
- Example 2 Affinity of humanized anti-EphA4 monoclonal antibody to human EphA4 The binding affinity of antibody B obtained in Example 1 to human EphA4 was determined by surface plasmon resonance (SPR method) using Biacore T200 (GE Healthcare). did.
- SPR method surface plasmon resonance
- Biacore T200 Biacore T200
- an anti-His antibody (GE Healthcare, 28-9950-56) was immobilized on the sensor chip CM5. Immobilization is performed by an amine coupling method using N-hydroxysuccinimide (NHS) and N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), and ethanolamine is used for blocking.
- NHS N-hydroxysuccinimide
- EDC N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride
- ethanolamine is used for blocking.
- the binding affinity (KD value) of antibody B to human EphA4 was 1.34 ⁇ 10-9 M (FIG. 11). It was found that antibody B showed almost the same affinity as antibody A before humanization.
- Example 3 EphA4 cleavage promoting activity of humanized anti-EphA4 monoclonal antibody in hippocampal neurons
- the antibody B obtained in Example 1 was evaluated for EphA4 cleavage promoting activity using hippocampal neurons according to the following steps. Rat hippocampal neurons seeded in 96-weldish (Falcon) were treated with antibody B (2.0, 6.7, 20 nM) and the ⁇ -secretase inhibitor CompoundE (50 nM, Enzo Life Sciences) 24 hours later with PBS.
- the cells were washed with (Wako Junyaku), SDS sample buffer (Laemmli sample buffer (Bio-Rad), 5% 2-mercaptoethanol (Bio-Rad)) was added, and the cells were collected and boiled for 5 minutes. SDS-PAGE was performed using this sample, Western blotting was performed using an anti-EphA4 monoclonal antibody (Abnova), band intensity was quantified, and the value of EphA4C terminal fragment / total length EphA4 was calculated.
- SDS sample buffer Laemmli sample buffer (Bio-Rad)
- 2-mercaptoethanol Bio-Rad
- Antibody B promoted the EphA4 cleavage reaction in hippocampal neurons in a concentration-dependent manner (Fig. 12).
- Example 4 Human EphA4-human ligand binding inhibitory activity of humanized anti-EphA4 monoclonal antibody
- Anti-alkaline phosphatase antibody (Thermo SCIENTIFIC) was coated on wells of 96-well plates (Nunc). After incubating overnight at 4 ° C., wells were blocked at room temperature for 1 hour with 1% Block Ace (DS Pharma Biomedical).
- the wells were inoculated with human EphA4 extracellular space-SEAP-His protein (final concentration 10 nM) and incubated at room temperature for 1 hour. After washing three times, the wells were serially diluted with ligand B (0, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000, 3000 nM) was added.
- a biotinylated human EphrinA5-Fc chimera (R & D Systems, final concentration 0.7 nM) and a biotinylated human EphrinB3-Fc chimera (R & D Systems, final concentration 2.3 nM) were used.
- horseradish peroxidase-labeled streptavidin (GE Healthcare) was added, and the mixture was incubated at room temperature for 1 hour.
- TMBZ (3,3', 5,5'-tetramethylbenzidine, Sigma) solution was added to the wells, and the mixture was incubated for 2 to 5 minutes at room temperature.
- An equal amount of reaction arrest solution (1NH 2 SO 4 , Wako Pure Chemical Industries, Ltd.) was added to the wells, and the absorbance at 450 nm was read by a microplate reader (Molecular Devices or PerkinElmer).
- Antibody B suppressed the binding between human EphA4 and human ligand in a concentration-dependent manner, and the IC50 values for human EphrinA5 and EphrinB3 binding were about 4.9 nM and 1.6 nM, respectively. Therefore, it was found that antibody B strongly inhibits the binding between human EphA4 and human ligand, and exhibits almost the same inhibitory activity as antibody A before humanization (FIG. 13).
- Example 5 Mouse EphA4-mouse ligand binding inhibitory activity of humanized anti-EphA4 monoclonal antibody With respect to the antibody B obtained in Example 1, the binding inhibitory activity between mouse EphA4 and mouse ligand was evaluated according to the following steps. Anti-alkaline phosphatase antibody (Thermo SCIENTIFIC) was coated on wells of 96-well plates (Nunc). After incubating overnight at 4 ° C., wells were blocked at room temperature for 1 hour with 1% Block Ace (DS Pharma Biomedical).
- Anti-alkaline phosphatase antibody Thermo SCIENTIFIC
- mouse EphA4 extracellular space-SEAP-His protein was added to the wells (final concentration 10 nM) and incubated for 1 hour at room temperature. After washing three times, the wells were serially diluted with ligand B (0, 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000, 3000 nM) was added.
- biotinylated mouse EphrinA1-Fc chimera R & D Systems, final concentration 6 nM
- biotinylated mouse EphrinB2-Fc chimera R & D Systems, final concentration 2.5 nM
- TMBZ horseradish peroxidase-labeled streptavidin
- TMBZ TMBZ (3,3', 5,5'-tetramethylbenzidine, Sigma) solution was added to the wells, and the mixture was incubated for 2 minutes at room temperature.
- An equal amount of reaction arrest solution (1NH 2 SO 4 , Wako Pure Chemical Industries, Ltd.) was added to the wells, and the absorbance at 450 nm was read by a microplate reader (Molecular Devices or PerkinElmer).
- Antibody B suppressed the binding between mouse EphA4 and mouse ligand in a concentration-dependent manner, and the IC50 values for mouse EphrinA1 and EphrinB2 binding were about 8.7 nM and 4.2 nM, respectively. Therefore, it was found that antibody B strongly inhibits the binding between mouse EphA4 and mouse ligand, and exhibits almost the same inhibitory activity as antibody A before humanization (FIG. 14).
- Example 6 Selectivity of humanized anti-EphA4 monoclonal antibody for human Eph receptor Similar to the method for preparing mouse EphA4 extracellular region-SEAP-His protein described in Reference Example 1, each human Eph receptor (EphA1, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, EphA8, EphA10, EphB1, EphB2, EphB3, EphB4, EphB6) signal sequences and DNA sequences encoding extracellular regions using tissue-derived Total RNA by RT-PCR. It was amplified and cloned into a pENTR1A vector (Invitrogen / Life Technologies) having a DNA sequence encoding the SEAP protein and histidine tag.
- pENTR1A vector Invitrogen / Life Technologies
- each human Eph receptor the DNA sequence encoding the SEAP protein and the histidine tag are transferred to the pcDNA3.1_rfcB vector by the LR reaction of Gateway System (Invitrogen / LifeTechnologies), and each Eph in human is transferred.
- a vector that expresses a protein in which a SEAP protein and a His tag are fused to the extracellular region of the receptor referred to as "Eph receptor extracellular space-SEAP-His protein" ("Eph receptor extracellular space-SEAP-His protein expression vector"). ") was constructed.
- each human Eph receptor extracellular space-SEAP-His protein expression vector was introduced into Expi293F cells (Gibco / Thermo Fisher). After 5 days of incubation (5% CO 2 , 37 ° C.), the culture supernatant was collected and centrifuged at 1500 rpm for 5 minutes at room temperature. The centrifugation supernatant was filtered through a 0.45 ⁇ m filter (Millipore).
- the binding activity of the human Eph receptor was evaluated according to the following steps. Rabbit anti-6-His antibody (Bethyl Laboratories) was coated on wells of 96-well plates (Nunc). After incubating overnight at 4 ° C., wells were blocked at room temperature for 1 hour with 1% Block Ace (DS Pharma Biomedical). After washing 3 times with 0.05% Tween20 / PBS (Thermo SCIENTIFIC), each well was inoculated with each human Eph receptor extracellular space-SEAP-His protein (final concentration 1 nM) and incubated for 1 hour at room temperature. ..
- antibody B specifically binds to human EphA4 among the human Eph receptor families, similar to antibody A before humanization (FIG. 15).
- Example 7 Selectivity of humanized anti-EphA4 monoclonal antibody for mouse Eph receptor
- each Eph receptor in mice (EphA1, EphA3, EphA4, EphA5).
- EphA6, EphA7, EphA8, EphA10, EphB1, EphB2, EphB3, EphB4, EphB6) and DNA sequences encoding extracellular regions are amplified by RT-PCR using tissue-derived Total RNA and human IgG.
- mice It was cloned into a pENTR1A vector (Invitrogen / LifeTechnologies) having a DNA sequence encoding the Fc region of 1 and the histidine tag.
- EphA1, EphA3, EphA4, EphA5, EphA6, EphA7, EphA8, EphA10, EphB1, EphB2, EphB3, EphB4, EphB6) of mice are encoded.
- the DNA sequence was transferred to the pcDNA3.1_rfcB vector by the LR reaction of Gateway System (Invitrogen / LifeTechnologies) to construct the extracellular space-Fc-His protein expression vector of each Eph receptor in mice.
- Gateway System Invitrogen / LifeTechnologies
- the signal sequence of mouse EphA2 and the DNA sequence encoding the extracellular region were amplified by RT-PCR using tissue-derived Total RNA, and Fc and Fc and A mouse EphA2 extracellular region-Fc-His protein expression vector was constructed by cloning into a pcDNA3.1 vector having a DNA sequence encoding a histidine tag.
- each Eph receptor extracellular space-Fc-His protein expression vector of mice was introduced into Expi293F cells (Gibco / Thermo Fisher). After culturing for 5 days (5% CO2, 37 ° C., 120 rpm), the culture supernatant was collected and centrifuged at 1500 rpm for 5 minutes at room temperature. The centrifugation supernatant was filtered through a 0.45 ⁇ m filter (Millipore).
- the binding activity of the mouse Eph receptor was evaluated according to the following steps. Rabbit anti-6-His antibody (Bethyl Laboratories) was coated on wells of 96-well plates (Nunc). After incubating overnight at 4 ° C., wells were blocked at room temperature for 1 hour with 1% Block Ace (DS Pharma Biomedical). After washing 3 times with 0.05% Tween20 / PBS (Thermo SCIENTIFIC), each well was inoculated with each Eph receptor extracellular space-Fc-His protein (final concentration 1 nM) of mice and incubated at room temperature for 1 hour. ..
- Antibody B had a specific binding activity only to mouse EphA4 among the mouse Eph receptor families (FIG. 16).
- Example 8 Reactivity of humanized anti-EphA4 monoclonal antibody to mouse, rat, monkey and human EphA4
- the binding activity of antibody B to various EphA4s was evaluated according to the following steps.
- Anti-alkaline phosphatase antibody (Thermo SCIENTIFIC) was coated on wells of 96-well plates (Nunc). After incubating overnight at 4 ° C., wells were blocked at room temperature for 1 hour with 1% Block Ace (DS Pharma Biomedical). After washing 3 times with 0.05% Tween20 / PBS (Thermo SCIENTIFIC), the wells were inoculated with mouse, rat, monkey and human EphA4 extracellular space-SEAP-His protein (final concentration 1 nM) for 1 hour at room temperature. Incubated.
- Antibody B had the same binding activity in all of mouse, rat, monkey and human EphA4 (Fig. 17).
- Example 9 Reactivity of humanized anti-EphA4 monoclonal antibody to human EphA4 extracellular region, ligand-binding domain, fibronectin type III domain 1, fibronectin type III domain 2
- Antibodies B obtained in Example 1 have various human EphA4 intra-domains.
- the evaluation of the binding activity with was performed according to the following steps. Rabbit anti-6-His antibody (Bethyl Laboratories) was coated on wells of 96-well plates (Nunc). After incubating overnight at 4 ° C., wells were blocked at room temperature for 1 hour with 1% Block Ace (DS Pharma Biomedical).
- human EphA4 extracellular space-MBP-His protein, human EphA4 ligand binding domain-MBP-His protein, human EphA4 fibronectin type III domain 1- MBP-His protein and human EphA4 fibronectin type III domain 2-MBP-His protein (final concentration 10 nM) were seeded and incubated at room temperature for 1 hour. After washing 3 times, antibody B (final concentration 10 nM) was added to the wells and incubated at room temperature for 1 hour.
- Horseradish peroxidase-labeled rabbit anti-human IgG Fc ⁇ fragment antibody (Jackson ImmunoResearch Laboratories) was added and incubated for 1 hour at room temperature. After washing 5 times, add TMB (KPL) solution to the wells, and after confirming appropriate color development, add an equal amount of reaction stop solution (2NH 2 SO 4 , Wako Pure Chemical Industries, Ltd.) to the wells, and use a microplate reader (PerkinElmer). The absorbance at 450 nm and 650 nm was read.
- Antibody B had binding activity to the human EphA4 extracellular space (ECD) and ligand binding domain (LBD) (FIG. 18). It did not react with fibronectin type III domain 1 (FN1) and fibronectin type III domain 2 (FN2). Therefore, it was found that antibody B specifically binds to the ligand-binding domain of the extracellular region of human EphA4.
- Example 10 Increasing effect of humanized anti-EphA4 monoclonal antibody on the spine number of hippocampal neurons
- Preparation of rat hippocampal neurons was performed as described in Reference Example 1 (B).
- the EGFP gene was introduced into rat hippocampal neurons using Nucleofector (Lonza) and seeded on a 24-well plate (Falcon) containing a cover glass coated with poly-L lysine (Matsunami Glass Ind.).
- Counting of spines using hippocampal neurons was performed according to the following steps. Control antibody (human IgG 2 ; Sigma) or antibody B (human IgG 2; Sigma) or antibody B (human IgG 2; Sigma) or antibody B (human IgG 2; Sigma) or antibody B (human IgG 2; 6.7, 20 nM) was treated for 24 hours. Then, the cover glass was transferred to 2% PFA (Wako Pure Chemical Industries, Ltd.) / 4% Sucrose (Wako Pure Chemical Industries, Ltd.) / PBS and allowed to stand for 20 minutes to fix the cells.
- the cells were washed 3 times with PBS, 0.25% Triton X-100 (Wako Pure Chemical Industries, Ltd.) / PBS was added, and cell permeation treatment was performed for 15 minutes. Remove the liquid, transfer the cover glass to 2% BSA (Sigma) / 0.25% TritonX-100 / OPTI-MEM (GIBCO), block for 1 hour, and then apply anti-GFP antibody (Nacalai Tesque) for 1 hour. The reaction was carried out for 30 minutes. The primary antibody solution was removed, the cells were washed 3 times with PBS, and then the secondary antibody was reacted for 1 hour.
- Antibody B increased the number of spines in hippocampal neurons (Fig. 19). This result indicates that antibody B has the activity of stabilizing spines in hippocampal neurons.
- Example 11 Human EphA4 cleavage promoting activity of humanized anti-EphA4 monoclonal antibody With respect to the antibody B obtained in Example 1, the cleavage promoting activity against human EphA4 was evaluated according to the following steps. Preparation of rat hippocampal neurons was performed as described in Reference Example 1 (B). A human EphA4-HA protein expression vector was introduced into rat hippocampal neurons using a Nucleifier (Lonza) and seeded on a polyL-lysine-coated 96-weldish (Falcon).
- the seeded rat hippocampus neurons were treated with antibody B (6.7, 20, 67 nM) and the ⁇ -secretase inhibitor CompoundE (50 nM, Enzo Life Sciences), and washed with PBS (Wako Pure Drug) about 24 hours later. Then, SDS sample buffer (Laemmli sample buffer (Bio-Rad), 5% 2-mercaptoethanol (Bio-Rad)) was added to collect the cells, and the cells were boiled for 5 minutes. SDS-PAGE was performed using this sample, Western blotting was performed using a rat anti-HA monoclonal antibody (Roche), the band intensity was quantified, and the value of EphA4C terminal fragment / total length EphA4 was calculated.
- SDS sample buffer Laemmli sample buffer (Bio-Rad), 5% 2-mercaptoethanol (Bio-Rad)
- Antibody B promoted the human EphA4 cleavage reaction in hippocampal neurons (Fig. 20).
- Example 12 Involvement of MMP and ADAM in the spine-increasing effect of humanized anti-EphA4 monoclonal antibody on hippocampal neurons
- Preparation of rat hippocampal neurons was performed as described in Reference Example 1 (B).
- the EGFP gene was introduced into some rat hippocampal neurons using Nucleofector (Lonza) and seeded on a 24-well plate (Falcon) containing a cover glass coated with poly-L lysine (Matsunami Glass Ind.).
- Control antibody human IgG 2 ; Sigma or antibody B (human IgG 2; Sigma) or antibody B (human IgG 2; Sigma) or antibody B (human IgG 2; Sigma) or antibody B (human IgG 2; Sigma) or antibody B (human IgG 2; Sigma) or antibody B (human IgG 2; 20 nM) and DMSO (Sigma) or GM6001 (2.5 ⁇ M, MedChemExpress), an inhibitor of MMP and ADAM, were treated for 24 hours.
- the cover glass was transferred to 2% PFA (Wako Pure Chemical Industries, Ltd.) / 4% Sucrose (Wako Pure Chemical Industries, Ltd.) / PBS and allowed to stand for 20 minutes to fix the cells. After removing the fixation solution, the cells were washed 3 times with PBS, 0.25% Triton X-100 (Wako Pure Chemical Industries, Ltd.) / PBS was added, and cell permeation treatment was performed for 15 minutes. Except for 0.25% TritonX-100 / PBS, transfer the cover glass to 2% BSA (Sigma) / 0.25% TritonX-100 / OPTI-MEM (GIBCO), block for 1 hour, and then anti-GFP.
- the antibody (Nacalai Tesque) was reacted for 1 hour and 30 minutes.
- the primary antibody solution was removed, the cells were washed 3 times with PBS, and then the secondary antibody was reacted for 1 hour.
- Prolong Gold antibody reagent (Molecular probes) was added and encapsulated, and observation was performed with LSM800 (ZEISS).
- the above-mentioned experiments were carried out three times, and neurons were extracted from two cover glasses for each experiment, and the spines on each dendrite were counted using the image analysis software Imaris (registered trademark) (Bitplane). , The number of spines per 10 ⁇ m in each neuron was calculated.
- Example 13 Human iPS cell-derived motor neuron protective effect in in vitro ALS model of humanized anti-EphA4 monoclonal antibody
- A Maintenance culture of human iPS cells The maintenance culture of human iPS cells was performed according to the following steps. Human iPS cells (201B7) cryopreserved in a Stem cell banker (Takara) in liquid nitrogen were taken out from the liquid nitrogen air layer and preheated to 37 ° C. in human iPS cell culture medium (Essential 8, Thermovier scientific). ) Suspended in 5 mL and thawed.
- the culture medium of human iPS cells in the subconfluent state is aspirated, washed with 2 mL of PBS (WAKO), and then 1 mL of Accutase (Nacalai Tesque) is added, and 5 in a CO 2 incubator (37 ° C., 5% CO 2 ). Incubated for minutes.
- Human iPS cells were dissociated into single cells by suspension in 4 mL of human iPS cell culture medium containing 10 ⁇ M Y-27632 and then recovered in a 15 mL conical tube.
- human iPS cells were suspended in 1 mL of human iPS cell culture medium containing 10 ⁇ M Y-27632. The number of cells was counted, 2 ⁇ 10 5 human iPS cells were suspended in 4 mL of human iPS cell culture medium, and then seeded in a ⁇ 60 mm cell culture dish coated with 0.3 ⁇ g / cm 2 iMatrix-511 and CO. Incubation was carried out in 2 incubators (37 ° C., 5% CO 2 ). For the experiment, human iPS cells that had been subcultured at least once were used.
- Dulvecco's Modified Eagle Medium (Thermovisher Scientific) containing 10% FBS (Thermovisher Scientific) and 1% penicillin streptomycin (Nacalai Tesque) was diluted with 10% FBS (Thermovisher Scientific) and 10% Penicillin Streptomycin (Nacalai Tesque). Then, impurities other than single cells were filtered by a cell strainer (Corning) and centrifuged at 1500 rpm for 5 minutes. The supernatant was aspirated, cells were diluted to 4 mL of new 10% FBS-DMEM, seeded in ⁇ 60 mm cell culture dishes for each individual, and cultured at 37 ° C.
- Genotyping of mutant human SOD1 was performed using the REDExtract-N-Amp TM Tissue PCR kit (Sigma).
- the cell suspension collected during subculture of astrocytes was transferred to a 1.5 mL tube and centrifuged at 1500 rpm for 3 minutes. After centrifugation, the supernatant was aspirated, 1 mL of PBS was added to the cells, washed, centrifuged again, and then aspirated. 50 ⁇ L of the extract solution and 12.5 ⁇ L of the tissue preparation solution were mixed and added to the sample. After mixing, transfer to a polymerase chain reaction (PCR) tube and GeneAmp®.
- PCR polymerase chain reaction
- the reaction was carried out in PCR system9700 (Applied biosystems (registered trademark)) at 55 ° C. for 10 minutes and 95 ° C. for 3 minutes, and then 50 ⁇ L of the neutralizing solution attached to the kit was added to prepare genomic DNA.
- PCR system9700 Applied biosystems (registered trademark)
- Genomic PCR was performed using the extracted genomic DNA with the composition shown in Table 4.
- the primer sequences used in PCR are shown in Table 5.
- electrophoresis was performed on a 1% agarose gel / 100 V / 20 minutes. Two bands of the internal standard 324 bp and the mutant human SOD1 (G93A) 236 bp were detected as mutant human SOD1 (G93A) expressing astrocytes.
- Red mix REDExtract-N-Amp PCR reaction mix.
- iPS cells Human iPS cells are subjected to DFK20 medium (20% Knockout thermoreprecement (KSR, Thermo Fisher Scientific), 1% Non-essential amino acid (NEAA, Thermo Fisher Scientific) After suspension in DMEM / F12 (Thermorphisher Scientific) containing / mL Streptomycin (Nacalai Tesque) and 100 ⁇ M ⁇ -mercaptoethanol (Thermorphisher Scientific), the number of cells was counted.
- KSR Knockout thermoreprecement
- NEAA Non-essential amino acid
- DFK20 medium containing 10 ⁇ M SB431542 (Sigma), 100 nM LDN193189 (Sigma), 3 ⁇ M CHIR99021 (Cayman Chemical), 10 ⁇ M Y-27632 was suspended in 2 mL for 3 ⁇ 10 5 human iPS cells and 6 wells with low adhesion.
- the cells were seeded in 1 well of a cell culture plate (Corning) and cultured in a CO 2 incubator (37 ° C., 5% CO 2 ).
- human iPS cell differentiated cell masses SFEBs
- SFEBs human iPS cell differentiated cell masses
- SFEBs are gently suspended in DFK20 medium containing 10 ⁇ M SB431542, 100 nM LDN193189, 3 ⁇ M CHIR99021 (Cayman), 5 ⁇ M Y-27632, and 1 ⁇ M Retinoic Acid (Sigma), and returned to the original well.
- Exchanged Medium exchange was carried out in the same manner on the 5th day of culture. However, the medium was exchanged at a concentration of Y-27632 of 2.5 ⁇ M (other compounds were the same as on the third day of culture).
- SFEBs were collected together with the medium in a 15 mL conical tube and allowed to stand at room temperature for 10 minutes to precipitate SFEBs.
- This supernatant is aspirated and contains 3 mL of DFK5 medium (5% KSR, 1% NEAA, 1% GlutaMAX-I Streptomycin, 100 units / mL penicillin- SFEBs were suspended in DMEM / F12) containing 100 ⁇ M ⁇ -mercaptoethanol, returned to the original wells, and cultured in a CO 2 incubator (37 ° C., 5% CO 2 ). Then, every 2-3 days, the medium was exchanged in the same process as on the 7th day of culture, and the differentiation of human iPS cells into motor neurons was induced.
- DFK5 medium 5% KSR, 1% NEAA, 1% GlutaMAX-I Streptomycin, 100 units / mL penicillin- SFEBs were suspended in DMEM / F12
- DMEM / F12 100 ⁇ M ⁇ -mercaptoethanol
- SFEBs were collected together with the medium in a 15 mL conical tube and allowed to stand at room temperature for 5 minutes to precipitate SFEBs.
- the supernatant was aspirated, 2 mL of Accutase containing 10 ⁇ M Y-27632 was added, and the mixture was incubated in a 37 ° C. constant temperature water bath for 10 minutes.
- the cell mass was dispersed by pipetting 30 times with a P1000 pipette, and then the enzyme reaction was stopped with 10 mL of DFK5 medium containing 10 ⁇ M Y-27632.
- the cell suspension was collected in a new 15 mL conical tube, centrifuged at 1000 rpm for 5 minutes at room temperature, and the supernatant was aspirated. After resuspending the cells in DFK5 medium containing 10 ⁇ M Y-27632, filtration was performed with a cell strainer (Corning), and then the number of cells was counted.
- Co-culture medium (2% B27 Suspension (Thermovisher Scientific), 10 ⁇ M Y-27632, 1% GlutaMax-I Suspension, 100 units / mL penicillin-100 ⁇ g / mL Streptomycin-containing Neurobasic cells (Neurobisal) Cell 5 cells with Streptomycin in 10 ⁇ M Y-27632 It was prepared in a suspension of / mL and divided into a control group, a peptide-added group and a drug treatment group. The drug was diluted using a co-culture medium.
- mouse-derived wild-type astrosites or mutant human SOD1 (G93A) -expressing astrosites were previously seeded in 8 ⁇ 10 4 cells / well in an 8-well chamber at 200 ⁇ L / well, and astrosites and motor neurons were seeded.
- the number of motor neurons observed in the co-culture of wild-type astrosite and motor neurons was controlled as the number of motor neurons observed as co-cultured cells.
- Co-culture of the site and motor neurons was performed, and the conditions were added with vehicle (1% co-culture medium) and antibody B (10, 30, 100 nmol / L). Under each condition, in a CO 2 incubator (37 ° C., 5%).
- FIG. 22 shows a simple schematic diagram showing the steps of the evaluation system.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(1)抗EphA4抗体を含む、筋萎縮性側索硬化症(ALS)を治療するための医薬組成物であって、
前記抗EphA4抗体は、
(a)配列番号44に示すアミノ酸配列からなる重鎖CDR1;
(b)配列番号27に示すアミノ酸配列からなる重鎖CDR2;および
(c)配列番号28に示すアミノ酸配列からなる重鎖CDR3を含む重鎖;および
(d)配列番号29に示すアミノ酸配列からなる軽鎖CDR1;
(e)配列番号30に示すアミノ酸配列からなる軽鎖CDR2;および
(f)配列番号31に示すアミノ酸配列からなる軽鎖CDR3を含む軽鎖
を含む、
医薬組成物。
前記抗EphA4抗体は、ヒト化されている、
医薬組成物。
前記抗EphA4抗体は、EphA4に特異的に結合し、EphA4の切断を促進する、
医薬組成物。
前記抗EphA4抗体は、EphA4に特異的に結合し、EphA4とephrinとの結合を阻害する、
医薬組成物。
前記重鎖は配列番号45に示すアミノ酸配列からなる可変領域を含み、
前記軽鎖は配列番号46に示すアミノ酸配列からなる可変領域を含む、
医薬組成物。
前記重鎖の定常領域および前記軽鎖の定常領域がヒト抗体由来のアミノ酸配列を含む、
医薬組成物。
前記重鎖の定常領域はヒトIgGの定常領域である、
医薬組成物。
前記ヒトIgGの定常領域はヒトIgG2の定常領域である、
医薬組成物。
前記ヒトIgG2の定常領域は、配列番号47に示すアミノ酸配列を含む、
医薬組成物。
前記軽鎖の定常領域はヒトIgκの定常領域である、
医薬組成物。
前記ヒトIgκの定常領域は、配列番号48に示すアミノ酸配列を含む、
医薬組成物。
前記抗EphA4抗体は、重鎖および軽鎖を含み、
前記重鎖は、配列番号59に示すアミノ酸配列を含み、
前記軽鎖は、配列番号60に示すアミノ酸配列を含み、
前記重鎖のC末端リシンが欠失されていてもよい
医薬組成物。
前記重鎖のC末端リシンが欠失されている、
医薬組成物。
前記抗EphA4抗体は、重鎖および軽鎖を含み、
前記重鎖は、配列番号59に示すアミノ酸配列を含み、
前記軽鎖は、配列番号60に示すアミノ酸配列を含む、
医薬組成物。
前記抗EphA4抗体は、重鎖および軽鎖を含み、
前記重鎖は、配列番号59に示すアミノ酸配列を含み、
前記軽鎖は、配列番号60に示すアミノ酸配列を含み、
前記重鎖のC末端リシンが欠失されている、
医薬組成物。
少なくとも一つの薬剤学的に許容される担体をさらに含む、
医薬組成物。
前記抗EphA4抗体は、
(a)配列番号44に示すアミノ酸配列からなる重鎖CDR1;
(b)配列番号27に示すアミノ酸配列からなる重鎖CDR2;および
(c)配列番号28に示すアミノ酸配列からなる重鎖CDR3を含む重鎖;および
(d)配列番号29に示すアミノ酸配列からなる軽鎖CDR1;
(e)配列番号30に示すアミノ酸配列からなる軽鎖CDR2;および
(f)配列番号31に示すアミノ酸配列からなる軽鎖CDR3を含む軽鎖
を含む、
抗EphA4抗体。
前記抗EphA4抗体は、ヒト化されている、
抗EphA4抗体。
前記抗EphA4抗体は、EphA4に特異的に結合し、EphA4の切断を促進する、
抗EphA4抗体。
前記抗EphA4抗体は、EphA4に特異的に結合し、EphA4とephrinとの結合を阻害する、
抗EphA4抗体。
前記重鎖は配列番号45に示すアミノ酸配列からなる可変領域を含み、
前記軽鎖は配列番号46に示すアミノ酸配列からなる可変領域を含む、
抗EphA4抗体。
前記重鎖の定常領域および前記軽鎖の定常領域がヒト抗体由来のアミノ酸配列を含む、
抗EphA4抗体。
前記重鎖の定常領域はヒトIgGの定常領域である、
抗EphA4抗体。
前記ヒトIgGの定常領域はヒトIgG2の定常領域である、
抗EphA4抗体。
前記ヒトIgG2の定常領域は、配列番号47に示すアミノ酸配列を含む、
抗EphA4抗体。
前記軽鎖の定常領域はヒトIgκの定常領域である、
抗EphA4抗体。
前記ヒトIgκの定常領域は、配列番号48に示すアミノ酸配列を含む、
抗EphA4抗体。
前記抗EphA4抗体は、重鎖および軽鎖を含み、
前記重鎖は、配列番号59に示すアミノ酸配列を含み、
前記軽鎖は、配列番号60に示すアミノ酸配列を含み、
前記重鎖のC末端リシンが欠失されていてもよい
抗EphA4抗体。
前記重鎖のC末端リシンが欠失されている、
抗EphA4抗体。
前記抗EphA4抗体は、重鎖および軽鎖を含み、
前記重鎖は、配列番号59に示すアミノ酸配列を含み、
前記軽鎖は、配列番号60に示すアミノ酸配列を含む、
抗EphA4抗体。
前記抗EphA4抗体は、重鎖および軽鎖を含み、
前記重鎖は、配列番号59に示すアミノ酸配列を含み、
前記軽鎖は、配列番号60に示すアミノ酸配列を含み、
前記重鎖のC末端リシンが欠失されている、
抗EphA4抗体。
前記医薬組成物は、少なくとも一つの薬剤学的に許容される担体を含む、
抗EphA4抗体の使用。
(1)疎水性:Met、Ala、Val、Leu、Ile;
(2)中性親水性:Asn、Gln、Cys、Ser、Thr;
(3)酸性:Asp、Glu;
(4)塩基性:His、Lys、Arg;
(5)鎖配向に影響を及ぼす残基:Gly、Pro;および
(6)芳香族:Trp、Tyr、Phe。
(a)配列番号44に示すアミノ酸配列からなる重鎖CDR1;
(b)配列番号27に示すアミノ酸配列からなる重鎖CDR2;
(c)配列番号28に示すアミノ酸配列からなる重鎖CDR3;
(d)配列番号29に示すアミノ酸配列からなる軽鎖CDR1;
(e)配列番号30に示すアミノ酸配列からなる軽鎖CDR2;および
(f)配列番号31に示すアミノ酸配列からなる軽鎖CDR3。
(A)マウス抗EphA4モノクローナル抗体の作製
マウスEphA4(Genbank Accession No. NP_031962.2、配列番号1)に結合するモノクローナル抗体を作製するため、マウスEphA4の細胞外領域(20~547位)(配列番号2)に分泌型アルカリフォスファターゼ(SEAP)およびヒスチジンタグを融合したタンパク質(以下、「マウスEphA4細胞外領域-SEAP-Hisタンパク質」という、配列番号3)を以下の工程により調製した。
ラット海馬ニューロンの調製は、以下の工程に従って行った。妊娠18日目のラット(日本チャールズ・リバー)から胎仔を取り出し、頭部を切開して脳を取り出した。実体顕微鏡下で海馬領域を切り出したのち、digestion溶液(137mM NaCl(和光純薬),5mM KCl(和光純薬),7mM Na2HPO4(和光純薬),25mM Hepes(DOJINDO)、0.5mg/mL DNase(Sigma),0.25%トリプシン(Life technologies))に入れて37℃で10分間振とうした。溶液を除き、20%Fetal bovine serum/Hanks緩衝液(Sigma)を加えた。液を除いて、Hanks緩衝液で2回洗浄したのち、Hanks緩衝液中で海馬組織をピペッティングして細胞懸濁液を作製した。培養液(Neurobasal medium(Life technologies)、1×B-27supplement(Life technologies)、0.5mM L-グルタミン(Life technologies))を入れたポリLリジンをコートした96ウェルディッシュ(Falcon)に細胞を播種した。
抗体Aの重鎖および軽鎖のシグナル配列、および可変領域をコードするDNA配列を、5’-RACE(5’-rapid amplification of cDNA ends)法によって増幅した。前記ハイブリドーマから、RNeasy(QIAGEN)を用いて全RNAを調製し、DNase(QIAGEN, RNase free DNase set)で処理した。cDNA合成キット(TAKARA)を用いて、前記全RNAから二本鎖cDNAを調製した。オリゴDNA ad29S(ACATCACTCCGT)(配列番号7)およびオリゴDNA ad29AS(ACGGAGTGATGTCCGTCGACGTATCTCTGCGTTGATACTTCAGCGTAGCT)(配列番号8)のアニーリングによって得られた5’アダプターを前記cDNAに付加した。得られたcDNAを、5’フォワードプライマー(5’-PCR4 primer、AGCTACGCTGAAGTATCAACGCAGAG) (配列番号9)および3’リバースプライマー(マウスIgG重鎖の増幅にはGCCAGTGGATAGACTGATGG(配列番号10)を用い、マウスIgκ軽鎖の増幅にはGATGGATACAGTTGGTGCAGC(配列番号11)を用いた)によって増幅した。増幅されたcDNAを、pCR2.1ベクター(Invitrogen/LifeTechnologies)に挿入した。抗体Aの遺伝子配列を、ABI3130XLを用いて解析した。本解析によって同定された抗体Aの遺伝子配列にコードされたアミノ酸配列として、重鎖シグナル配列は配列番号12に示す配列であり、重鎖可変領域は配列番号13に示す配列であり、軽鎖シグナル配列は配列番号14に示す配列であり、軽鎖可変領域は配列番号15に示す配列である。抗体Aの遺伝子配列をコードするヌクレオチド配列として、重鎖シグナル配列は配列番号16に示す配列であり、重鎖可変領域は配列番号17に示す配列であり、軽鎖シグナル配列は配列番号18に示す配列であり、軽鎖可変領域は配列番号19に示す配列である。
抗体AのマウスおよびヒトEphA4に対する結合親和性をBiacore T200(GE Healthcare)を用いた表面プラズモン共鳴(SPR法)により決定した。まず、抗His抗体(GE Healthcare、28-9950-56)をセンサーチップCM5へ固定化した。固定化は、N-ヒドロキシスクシンイミド(NHS)、および、N-エチル-N’-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(EDC)を用いたアミンカップリング法にて行い、ブロッキングにはエタノールアミンを用いた(センサーチップや固定化用試薬は、全てGE Healthcare社製)。固定化用緩衝液(10mM酢酸ナトリウム、pH4.5)を用いて3.5μg/mLに希釈し、Biacore T200付属のプロトコルに従い、センサーチップ上に固定した。マウスもしくはヒトEphA4細胞外領域-SEAP-His10をランニング緩衝液HBS-EP(GE Healthcare、BR-1001-88)を用いて希釈し、フローセル上に120秒間送液しキャプチャーさせた(10RU程度のキャプチャー量)。続いてHBS-EPを用いて100、50、25、12.5、6.3、3.2、1.6、0nMの範囲で系列希釈した抗体Aを120秒間センサーチップに添加し、添加時(結合相、120秒間)、および、添加終了後(解離相、600秒間)の結合反応曲線を順次観測した。各々の観測終了後に、4M MgCl2(60秒間、和光純薬)を添加してセンサーチップを再生した。得られた結合反応曲線に対して、システム付属ソフトBIA evaluationソフトを用いた1:1の結合モデルによるフィッティング解析を行い、マウスおよびヒトのEphA4に対する結合親和性(KD=kd/ka)を算出した。
抗体Aについて、海馬ニューロンを用いたEphA4切断促進活性の評価を以下の工程に従って行った。96ウェルディッシュ(Falcon)に播種したラット海馬ニューロンに、抗体A(2.0、6.7、20nM)およびγセクレターゼ阻害薬であるCompoundE(50nM、Enzo Life Sciences)を処置して24時間後にPBS(和光純薬)で洗浄して、SDS sample buffer(Laemmliサンプルバッファー(バイオ・ラッド)、5%2-メルカプトエタノール(バイオ・ラッド))を加えて細胞を回収し、5分間煮沸した。このサンプルを用いてSDS-PAGEを行い、抗EphA4モノクローナル抗体(Abnova)を用いたウェスタンブロッティングを行い、バンド強度を定量化し、EphA4C末端フラグメント/全長EphA4の値を算出した。
抗体Aについて、マウスEphA4とマウスリガンドとの結合阻害活性の評価は、以下の工程に従って行った。抗アルカリフォスファターゼ抗体(Thermo SCIENTIFIC)を、96ウェルプレート(Nunc)のウェル上にコートした。4℃にて一晩インキュベートした後、1%ブロックエース(DSファーマバイオメディカル)により、ウェルを室温にて1時間ブロッキングした。0.02% Tween20/PBS(Thermo SCIENTIFIC)で3回洗浄した後、ウェルにマウスEphA4細胞外領域-SEAP-Hisタンパク質を加え(最終濃度10nM)、室温にて1時間インキュベートした。3回洗浄した後、ウェルにリガンドと抗体Aを(0、0.003、0.01、0.03、0.1、0.3、1、3、10、30、100、300、1000、3000nM)を添加した。なお、リガンドにはビオチン化マウスEphrinA1-Fcキメラ(R&D Systems、最終濃度6nM)およびビオチン化マウスEphrinB2-Fcキメラ(R&D Systems、最終濃度2.5nM)を用いた。室温にて1時間インキュベートして3回洗浄した後、西洋ワサビペルオキシダーゼ標識ストレプトアビジン(GE Healthcare)を加え、室温にて1時間インキュベートした。3回洗浄した後、ウェルにTMBZ(3,3’,5,5’-テトラメチルベンジジン、Sigma)溶液を加え、2分、室温にてインキュベートした。ウェルに等量の反応停止溶液(1N H2SO4、和光純薬)を加え、マイクロプレートリーダー(PerkinElmer)により450nmの吸光度を読み取った。
抗体Aについて、ヒトEphA4とヒトリガンドとの結合阻害活性の評価は、以下の工程に従って行った。抗アルカリフォスファターゼ抗体(Thermo SCIENTIFIC)を、96ウェルプレート(Nunc)のウェル上にコートした。4℃にて一晩インキュベートした後、1%ブロックエース(DSファーマバイオメディカル)により、ウェルを室温にて1時間ブロッキングした。0.05% Tween20/PBS(Thermo SCIENTIFIC)で3回洗浄した後、ウェルにヒトEphA4細胞外領域-SEAP-Hisタンパク質を加え(最終濃度10nM)、室温にて1時間インキュベートした。3回洗浄した後、ウェルにリガンドと系列希釈した抗体A(0、0.003、0.01、0.03、0.1、0.3、1、3、10、30、100、300、1000、3000nM)を添加した。なお、リガンドにはビオチン化ヒトEphrinA5-Fcキメラ(R&D Systems、最終濃度0.7nM)およびビオチン化ヒトEphrinB3-Fcキメラ(R&D Systems、最終濃度2.3nM)を用いた。室温にて1時間インキュベートして3回洗浄した後、西洋ワサビペルオキシダーゼ標識ストレプトアビジン(GE Healthcare)を加え、室温にて1時間インキュベートした。3回洗浄した後、ウェルにTMBZ(3,3’,5,5’-テトラメチルベンジジン、Sigma)溶液を加え、2~5分、室温にてインキュベートした。ウェルに等量の反応停止溶液(1N H2SO4、和光純薬)を加え、マイクロプレートリーダー(Molecular DevicesまたはPerkinElmer)により450nmの吸光度を読み取った。
参考例1に記載のマウスEphA4細胞外領域-SEAP-Hisタンパク質の調製方法に従って、ヒトの各Ephレセプター(EphA1、EphA2、EphA3、EphA4、EphA5、EphA6、EphA7、EphA8、EphA10、EphB1、EphB2、EphB3、EphB4、EphB6)のシグナル配列と細胞外領域をコードするDNA配列を組織由来のTotal RNAを用いて、RT-PCRによって増幅し、SEAPおよびヒスチジンタグをコードするDNA配列を有するpENTR1Aベクター(Invitrogen/LifeTechnologies)にクローニングした。次に、ヒトの各Ephレセプターのシグナル配列と細胞外領域、SEAPおよびヒスチジンタグをコードするDNA配列をGateway System(Invitrogen/LifeTechnologies)のLR反応により、pcDNA3.1_rfcBベクターに移し、ヒトの各Ephレセプターの細胞外領域に対してSEAPとHisタグを融合したタンパク質(「Ephレセプター細胞外領域-SEAP-Hisタンパク質」という)を発現するベクター(「Ephレセプター細胞外領域-SEAP-Hisタンパク質発現ベクター」という)を構築した。
ウサギ抗6―His抗体(Bethyl Laboratories)を、96ウェルプレート(Nunc)のウェル上にコートした。4℃にて一晩インキュベートした後、1%ブロックエース(DSファーマバイオメディカル)により、ウェルを室温にて1時間ブロッキングした。0.05% Tween20/PBS(Thermo SCIENTIFIC)で3回洗浄した後、各ウェルにヒトの各Ephレセプター細胞外領域-SEAP-Hisタンパク質(最終濃度1nM)を播種し、室温にて1時間インキュベートした。3回洗浄した後、ウェルにヒトIgG溶液(100μg/mL、三菱ウェルファーマ)および抗体A(10μg/mL)を添加し、室温にて1時間インキュベートした。西洋ワサビペルオキシダーゼ標識ロバ抗マウスIgG抗体(Jackson ImmunoResearch Laboratories)を加え、室温にて1時間インキュベートした。3回洗浄した後、ウェルにTMBZ(3,3’,5,5’-テトラメチルベンジジン、Sigma)溶液を加え、適度な発色を確認したらウェルに等量の反応停止溶液(1N H2SO4、和光純薬)を加え、マイクロプレートリーダー(PerkinElmer)により450nmの吸光度を読み取った。
参考例1に記載のEphA4細胞外領域-Fc-Hisタンパク質の調製方法に従って、マウスの各Ephレセプター(EphA1、EphA3、EphA4、EphA5、EphA6、EphA7、EphA8、EphA10、EphB1、EphB2、EphB3、EphB4、EphB6)のシグナル配列と細胞外領域をコードするDNA配列を組織由来のTotal RNAを用いて、RT-PCRによって増幅し、ヒトIgG1のFc領域およびヒスチジンタグをコードするDNA配列を有するpENTR1Aベクター(Invitrogen/LifeTechnologies)にクローニングした。次に、マウスの各Ephレセプター(EphA1、EphA3、EphA4、EphA5、EphA6、EphA7、EphA8、EphA10、EphB1、EphB2、EphB3、EphB4、EphB6)のシグナル配列と細胞外領域、FcおよびヒスチジンタグをコードするDNA配列をGateway System(Invitrogen/LifeTechnologies)のLR反応により、pcDNA3.1_rfcBベクターに移し、マウスの各Ephレセプターの細胞外領域-Fc-Hisタンパク質発現ベクターを構築した。マウスEphA2の細胞外領域-Fc-Hisタンパク質発現ベクターの構築では、マウスEphA2のシグナル配列と細胞外領域をコードするDNA配列を組織由来のTotal RNAを用いて、RT-PCRによって増幅し、FcおよびヒスチジンタグをコードするDNA配列を有するpcDNA3.1ベクターにクローニングして、マウスEphA2細胞外領域-Fc-Hisタンパク質発現ベクターを構築した。
ウサギ抗6―His抗体(Bethyl Laboratories)を、96ウェルプレート(Nunc)のウェル上にコートした。4℃にて一晩インキュベートした後、1%ブロックエース(DSファーマバイオメディカル)により、ウェルを室温にて1時間ブロッキングした。0.05% Tween20/PBS(Thermo SCIENTIFIC)で3回洗浄した後、各ウェルにマウスの各Ephレセプター細胞外領域‐Fc-Hisタンパク質(最終濃度1nM)を播種し、室温にて1時間インキュベートした。3回洗浄した後、ウェルにヒトIgG溶液(100μg/mL、Sigma)および抗体A(10μg/mL)を添加し、室温にて1時間インキュベートした。西洋ワサビペルオキシダーゼ標識ロバ抗マウスIgG抗体(Jackson ImmunoResearch Laboratories)を加え、室温にて1時間インキュベートした。3回洗浄した後、ウェルにTMBZ(3,3’,5,5’-テトラメチルベンジジン、Sigma)溶液を加え、適度な発色を確認したらウェルに等量の反応停止溶液(1N H2SO4、和光純薬)を加え、マイクロプレートリーダー(PerkinElmer)により450nmの吸光度を読み取った。
マウス、ラット、サルおよびヒトEphA4細胞外領域-Fc-Hisタンパク質の作製は、以下の工程に従って行った。まず、参考例1に記載のEphA4細胞外領域-Fc-Hisタンパク質の調製方法に従って、サルEphA4細胞外領域-Fc-Hisタンパク質発現ベクターを構築した。ベクター構築において利用するサルEphA4のアミノ酸配列を配列番号32、その細胞外領域は配列番号33として示す。サルEphA4細胞外領域-Fc-Hisタンパク質発現ベクター、および参考例1に記載のマウス、ラットおよびヒトEphA4細胞外領域-Fc-Hisタンパク質発現ベクターを用いて、各種EphA4細胞外領域-Fc-Hisタンパク質を調製した。
ロバ抗ヒトIgG抗体(Jackson ImmunoResearch Laboratories)を、96ウェルプレート(Nunc)のウェル上にコートした。4℃にて一晩インキュベートした後、1%ブロックエース(DSファーマバイオメディカル)により、ウェルを室温にて1時間ブロッキングした。0.05% Tween20/PBS(Thermo SCIENTIFIC)で3回洗浄した後、ウェルにマウス、ラット、サルおよびヒトEphA4細胞外領域-Fc-Hisタンパク質(最終濃度1nM)を播種し、室温にて1時間インキュベートした。3回洗浄した後、ウェルにヒトIgG溶液(100μg/mL、三菱ウェルファーマ)および抗体A(0、0.00013、0.00064、0.0032、0.016、0.08、0.4、2、10、μg/mL)を添加し、室温にて1時間インキュベートした。西洋ワサビペルオキシダーゼ標識ロバ抗マウスIgG抗体(Jackson ImmunoResearch Laboratories)を加え、室温にて1時間インキュベートした。3回洗浄した後、ウェルにTMBZ(3,3’,5,5’-テトラメチルベンジジン、Sigma)溶液を加え、適度な発色を確認したらウェルに等量の反応停止溶液(1N H2SO4、和光純薬)を加え、マイクロプレートリーダー(PerkinElmer)により450nmの吸光度を読み取った。
ヒトEphA4の細胞外領域(ECD)、リガンド結合ドメイン(LBD)、フィブロネクチンIII型ドメイン1(FN1)あるいはフィブロネクチンIII型ドメイン2(FN2)とマルトース結合タンパク質(MBP)およびヒスチジンタグを融合したタンパク質(以下、「ヒトEphA4細胞外領域-MBP-Hisタンパク質」、「ヒトEphA4リガンド結合ドメイン-MBP-Hisタンパク質」、「ヒトEphA4フィブロネクチンIII型ドメイン1-MBP-Hisタンパク質」、および「ヒトEphA4フィブロネクチンIII型ドメイン2-MBP-Hisタンパク質」という)の作製は、以下の工程に従って行った。最初に、pcDNA3.4-ヒトEphA4細胞外領域、リガンド結合ドメイン、フィブロネクチンIII型ドメイン1、あるいはフィブロネクチンIII型ドメイン2-MBP-His発現ベクターを構築した。まず、ヒトEphA4のシグナル配列(配列番号34)あるいはプレプロトリプシンのシグナル配列(配列番号35)とヒトEphA4の各ドメインをコードするDNA配列をPCRによって増幅し、MBPおよびヒスチジンタグをコードするDNA配列を有するpcDNA3.4ベクター(Invitrogen/LifeTechnologies)にクローニングして、ヒトEphA4細胞外領域-MBP-Hisタンパク質、ヒトEphA4リガンド結合ドメイン-MBP-Hisタンパク質、ヒトEphA4フィブロネクチンIII型ドメイン1-MBP-Hisタンパク質、およびヒトEphA4フィブロネクチンIII型ドメイン2-MBP-Hisタンパク質の発現ベクターを構築した。ベクター構築において利用するヒトEphA4のアミノ酸配列を配列番号5、その細胞外領域は配列番号36、リガンド結合ドメインは配列番号37、フィブロネクチンIII型ドメイン1は配列番号38、フィブロネクチンIII型ドメイン2は配列番号39として示す。Expi293発現システム(Thermo SCIENTIFIC)を用いて、上記発現ベクターをExpi293F細胞(Thermo SCIENTIFIC)へ形質移入した。4日後に培養上清を回収し、0.45μmフィルター(Millipore)を通した。Amylose resin(NEB)を用いて粗精製を行い、Zeba Spin Desalting column(Thermo SCIENTIFIC)を用いてPBS(和光純薬)にバッファー置換した。Superdex200 10/300(GE Healthcare)にて単量体画分を分画精製した。
ウサギ抗6―His抗体(Bethyl Laboratories)を、96ウェルプレート(Nunc)のウェル上にコートした。4℃にて一晩インキュベートした後、1%ブロックエース(DSファーマバイオメディカル)により、ウェルを室温にて1時間ブロッキングした。0.02% Tween20/PBS(ナカライテスク)で2回洗浄した後、ウェルにヒトEphA4細胞外領域-MBP-Hisタンパク質、ヒトEphA4リガンド結合ドメイン-MBP-Hisタンパク質、ヒトEphA4フィブロネクチンIII型ドメイン1-MBP-Hisタンパク質、およびヒトEphA4フィブロネクチンIII型ドメイン2-MBP-Hisタンパク質(最終濃度10nM)を播種し、室温にて1時間インキュベートした。3回洗浄した後、ウェルに抗体A(最終濃度10nM)を添加し、室温にて1時間インキュベートした。西洋ワサビペルオキシダーゼ標識ヤギ抗マウスIgG Fcγフラグメント抗体(Jackson ImmunoResearch Laboratories)を加え、室温にて1時間インキュベートした。5回洗浄した後、ウェルにTMB溶液(KPL)を加え、適度な発色を確認したらウェルに等量の反応停止溶液(2N H2SO4、和光純薬)を加え、マイクロプレートリーダー(PerkinElmer)により450nmおよび650nmの吸光度を読み取った。
ラット海馬ニューロンの調製は、上記参考例1の(B)に記載されるように行った。ラット海馬ニューロンにNucleofector(Lonza)を用いてEGFP遺伝子を導入し、遺伝子導入を行わないラット海馬ニューロンと混合して、ポリLリジンをコートしたカバーガラス(松浪硝子工業)を入れた24ウェルプレート(Falcon)に播種した。
抗体A-Fabの調製は、以下の工程に従って行った。抗体A 101.1mgを、15 mg/mLの濃度で30mM L-システインおよび2mM EDTAを含む0.1Mリン酸ナトリウム緩衝液(pH7.0)に溶解した。この抗体溶液に、パパイン(Sigma)を抗体に対して1/200量加えて、37℃で18時間酵素消化を行った。抗体A酵素消化液は、PBSに対して透析したのち、遠心分離にて沈殿を除去した(生じた沈殿はPBSで再溶解して、遠心分離上清と混合した)。次に、抗体A-Fab以外の不純物を除去する目的で、以下の工程を行った。
1)Protein Aカラムによる精製
この酵素消化溶液を、PBSで平衡化した2mLのProSep vA High Capacity (Millipore)にアプライして、素通り画分および、PBSでの洗浄画分を回収した。
2)抗ヒトIgG Fcγ抗体を用いたアフィニティー精製
抗ヒトIgG Fcγ抗体(Jackson ImmunoResearch Laboratories)を、NHS-ActivatedSepharose 4FF(GE Healthcare)に共有結合させたアフィニティーカラムを、このSepharoseのマニュアルに従って調製した。このアフィニティーカラムに対して、上記1)で回収した溶液をチャージして、その素通り溶液とPBSでの洗浄液を回収した。
3)ゲルろ過による精製
上記2)で得た素通り画分を、限外ろ過膜を用いて濃縮した。Superose 12(GE Healthcare)をPBSで平衡化し、濃縮した標品をアプライして分離精製した。分離精製した画分の一部を、SDS-PAGEで分析して、純度高く抗体A-Fabを含む画分を回収してプールした。このようにして精製した標品を、抗体A-Fabとした。
以上の構造計算によって2.0Å分解能の複合体結晶構造を得た(R=0.212、Rfree=0.258)。
ヒト化抗EphA4抗体の調製
ヒト化抗体の可変領域を設計した。抗体Aのフレームワーク領域(FR)に対する高い相同性を基に、ヒト抗体のFRの中から、重鎖についてはIGHV3-33*03(配列番号42)、およびJH6(配列番号43)、軽鎖についてはIGKV1-17*01(配列番号40)、およびJK4(配列番号41)をヒト化抗体のFRとして選択した。その後、マウス抗体Aの3D構造予測モデルを用いて、CDRのアミノ酸と相互作用するFRにおけるアミノ酸を予測し、重鎖のCDR1にY32Fの変異を有する抗体AのCDR(配列番号44、27、28、および29-31)とともに移植し、ヒト化抗体の重鎖可変領域としてHK2-42(配列番号45)が設計され、ヒト化抗体の軽鎖可変領域としてL1-8(配列番号46)が設計された。移植したCDRのアミノ酸配列を表2に示し、核酸配列を表3に示す。
実施例1で得た抗体BのヒトEphA4に対する結合親和性をBiacore T200(GE Healthcare)を用いた表面プラズモン共鳴(SPR法)により決定した。まず、抗His抗体(GE Healthcare,28-9950-56)をセンサーチップCM5へ固定化した。固定化は、N-ヒドロキシスクシンイミド(NHS)、および、N-エチル-N’-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(EDC)を用いたアミンカップリング法にて行い、ブロッキングにはエタノールアミンを用いた(センサーチップや固定化用試薬は、全てGE Healthcare社製)。固定化用緩衝液(10mM酢酸ナトリウム、pH4.5)を用いて3.5μg/mLに希釈し、Biacore T200付属のプロトコルに従い、センサーチップ上に固定した。ヒトEphA4細胞外領域-SEAP-His10をランニング緩衝液HBS-EP(GE Healthcare、BR-1001-88)を用いて希釈し、フローセル上に120秒間送液しキャプチャーさせた(10RU程度のキャプチャー量)。続いてHBS-EPを用いて100、50、25、12.5、6.3、3.2、1.6、0nMの範囲で系列希釈した抗体Bを120秒間センサーチップに添加し、添加時(結合相、120秒間)、および、添加終了後(解離相、600秒間)の結合反応曲線を順次観測した。各々の観測終了後に、4M MgCl2(60秒間、和光純薬)を添加してセンサーチップを再生した。得られた結合反応曲線に対して、システム付属ソフトBIA evaluationソフトを用いた1:1の結合モデルによるフィッティング解析を行い、ヒトのEphA4に対する親和性(KD=kd/ka)を算出した。
実施例1で得た抗体Bについて、海馬ニューロンを用いたEphA4切断促進活性の評価は、以下の工程に従って行った。
96ウェルディッシュ(Falcon)に播種したラット海馬ニューロンに、抗体B(2.0、6.7、20nM)およびγセクレターゼ阻害薬であるCompoundE(50nM、Enzo Life Sciences)を処置して24時間後にPBS(和光純薬)で洗浄して、SDS sample buffer(Laemmliサンプルバッファー(バイオ・ラッド)、5% 2-メルカプトエタノール(バイオ・ラッド))を加えて細胞を回収し、5分間煮沸した。このサンプルを用いてSDS-PAGEを行い、抗EphA4モノクローナル抗体(Abnova)を用いたウェスタンブロッティングを行い、バンド強度を定量化し、EphA4C末端フラグメント/全長EphA4の値を算出した。
実施例1で得た抗体Bについて、ヒトEphA4とヒトリガンドとの結合阻害活性の評価は、以下の工程に従って行った。抗アルカリフォスファターゼ抗体(Thermo SCIENTIFIC)を、96ウェルプレート(Nunc)のウェル上にコートした。4℃にて一晩インキュベートした後、1%ブロックエース(DSファーマバイオメディカル)により、ウェルを室温にて1時間ブロッキングした。0.05%Tween20/PBS(Thermo SCIENTIFIC)で3回洗浄した後、ウェルにヒトEphA4細胞外領域-SEAP-Hisタンパク質(最終濃度10nM)を播種し、室温にて1時間インキュベートした。3回洗浄した後、ウェルにリガンドと系列希釈した抗体B (0、0.003、0.01、0.03、0.1、0.3、1、3、10、30、100、300、1000、3000nM)を添加した。なお、リガンドにはビオチン化ヒトEphrinA5-Fcキメラ(R&D Systems、最終濃度0.7nM)およびビオチン化ヒトEphrinB3-Fcキメラ(R&D Systems、最終濃度2.3nM)を用いた。室温にて1時間インキュベートして3回洗浄した後、西洋ワサビペルオキシダーゼ標識ストレプトアビジン(GE Healthcare)を加え、室温にて1時間インキュベートした。3回洗浄した後、ウェルにTMBZ(3,3’,5,5’-テトラメチルベンジジン、Sigma)溶液を加え、2~5分、室温にてインキュベートした。ウェルに等量の反応停止溶液(1N H2SO4、和光純薬)を加え、マイクロプレートリーダー(Molecular DevicesまたはPerkinElmer)により450nmの吸光度を読み取った。
実施例1で得た抗体Bについて、マウスEphA4とマウスリガンドとの結合阻害活性の評価は、以下の工程に従って行った。抗アルカリフォスファターゼ抗体(Thermo SCIENTIFIC)を、96ウェルプレート(Nunc)のウェル上にコートした。4℃にて一晩インキュベートした後、1%ブロックエース(DSファーマバイオメディカル)により、ウェルを室温にて1時間ブロッキングした。0.02% Tween20/PBS(Thermo SCIENTIFIC)で3回洗浄した後、ウェルにマウスEphA4細胞外領域-SEAP-Hisタンパク質を加え(最終濃度10nM)、室温にて1時間インキュベートした。3回洗浄した後、ウェルにリガンドと系列希釈した抗体B(0、0.003、0.01、0.03、0.1、0.3、1、3、10、30、100、300、1000、3000nM)を添加した。なお、リガンドにはビオチン化マウスEphrinA1-Fcキメラ(R&D Systems、最終濃度6nM)およびビオチン化マウスEphrinB2-Fcキメラ(R&D Systems、最終濃度2.5nM)を用いた。室温にて1時間インキュベートして3回洗浄した後、西洋ワサビペルオキシダーゼ標識ストレプトアビジン(GE Healthcare)を加え、室温にて1時間インキュベートした。3回洗浄した後、ウェルにTMBZ(3,3’,5,5’-テトラメチルベンジジン、Sigma)溶液を加え、2分、室温にてインキュベートした。ウェルに等量の反応停止溶液(1N H2SO4、和光純薬)を加え、マイクロプレートリーダー(Molecular DevicesまたはPerkinElmer)により450nmの吸光度を読み取った。
参考例1に記載のマウスEphA4細胞外領域-SEAP-Hisタンパク質の調製方法と同様に、ヒトの各Ephレセプター(EphA1、EphA2、EphA3、EphA4、EphA5、EphA6、EphA7、EphA8、EphA10、EphB1、EphB2、EphB3、EphB4、EphB6)のシグナル配列と細胞外領域をコードするDNA配列を組織由来のTotal RNAを用いて、RT-PCRによって増幅し、SEAPタンパク質およびヒスチジンタグをコードするDNA配列を有するpENTR1Aベクター(Invitrogen/LifeTechnologies)にクローニングした。次に、ヒトの各Ephレセプターのシグナル配列と細胞外領域、SEAPタンパク質およびヒスチジンタグをコードするDNA配列をGateway System(Invitrogen/LifeTechnologies)のLR反応により、pcDNA3.1_rfcBベクターに移し、ヒトの各Ephレセプターの細胞外領域に対してSEAPタンパク質とHisタグを融合したタンパク質(「Ephレセプター細胞外領域-SEAP-Hisタンパク質」という)を発現するベクター(「Ephレセプター細胞外領域-SEAP-Hisタンパク質発現ベクター」という)を構築した。
ウサギ抗6―His抗体(Bethyl Laboratories)を、96ウェルプレート(Nunc)のウェル上にコートした。4℃にて一晩インキュベートした後、1%ブロックエース(DSファーマバイオメディカル)により、ウェルを室温にて1時間ブロッキングした。0.05% Tween20/PBS(Thermo SCIENTIFIC)で3回洗浄した後、各ウェルにヒトの各Ephレセプター細胞外領域-SEAP-Hisタンパク質(最終濃度1nM)を播種し、室温にて1時間インキュベートした。3回洗浄した後、ウェルにヒトIgG溶液(100μg/mL、三菱ウェルファーマ)および抗体B(10μg/mL)を添加し、室温にて1時間インキュベートした。西洋ワサビペルオキシダーゼ標識ロバ抗ヒトIgG抗体(Jackson ImmunoResearch Laboratories)を加え、室温にて1時間インキュベートした。3回洗浄した後、ウェルにTMBZ(3,3’,5,5’-テトラメチルベンジジン、Sigma)溶液を加え、適度な発色を確認したらウェルに等量の反応停止溶液(1N H2SO4、和光純薬)を加え、マイクロプレートリーダー(PerkinElmer)により450nmの吸光度を読み取った。
参考例1に記載のEphA4細胞外領域-Fc-Hisタンパク質の調製方法に従って、マウスの各Ephレセプター(EphA1、EphA3、EphA4、EphA5、EphA6、EphA7、EphA8、EphA10、EphB1、EphB2、EphB3、EphB4、EphB6)のシグナル配列と細胞外領域をコードするDNA配列を組織由来のTotal RNAを用いて、RT-PCRによって増幅し、ヒトIgG1のFc領域およびヒスチジンタグをコードするDNA配列を有するpENTR1Aベクター(Invitrogen/LifeTechnologies)にクローニングした。次に、マウスの各Ephレセプター(EphA1、EphA3、EphA4、EphA5、EphA6、EphA7、EphA8、EphA10、EphB1、EphB2、EphB3、EphB4、EphB6)のシグナル配列と細胞外領域、FcおよびヒスチジンタグをコードするDNA配列をGateway System(Invitrogen/LifeTechnologies)のLR反応により、pcDNA3.1_rfcBベクターに移し、マウスの各Ephレセプターの細胞外領域-Fc-Hisタンパク質発現ベクターを構築した。マウスEphA2の細胞外領域-Fc-Hisタンパク質発現ベクターの構築では、マウスEphA2のシグナル配列と細胞外領域をコードするDNA配列を組織由来のTotal RNAを用いて、RT-PCRによって増幅し、FcおよびヒスチジンタグをコードするDNA配列を有するpcDNA3.1ベクターにクローニングして、マウスEphA2細胞外領域-Fc-Hisタンパク質発現ベクターを構築した。
ウサギ抗6―His抗体(Bethyl Laboratories)を、96ウェルプレート(Nunc)のウェル上にコートした。4℃にて一晩インキュベートした後、1%ブロックエース(DSファーマバイオメディカル)により、ウェルを室温にて1時間ブロッキングした。0.05% Tween20/PBS(Thermo SCIENTIFIC)で3回洗浄した後、各ウェルにマウスの各Ephレセプター細胞外領域‐Fc-Hisタンパク質(最終濃度1nM)を播種し、室温にて1時間インキュベートした。3回洗浄した後、ウェルにヒトIgG溶液(100μg/mL、Sigma)および抗体B(10μg/mL)を添加し、室温にて1時間インキュベートした。西洋ワサビペルオキシダーゼ標識ヤギ抗ヒトKappa Light Chain抗体(IBL)を加え、室温にて1時間インキュベートした。3回洗浄した後、ウェルにTMBZ(3,3’,5,5’-テトラメチルベンジジン、Sigma)溶液を加え、適度な発色を確認したらウェルに等量の反応停止溶液(1N H2SO4、和光純薬)を加え、マイクロプレートリーダー(PerkinElmer)により450nmの吸光度を読み取った。
抗アルカリフォスファターゼ抗体(Thermo SCIENTIFIC)を、96ウェルプレート(Nunc)のウェル上にコートした。4℃にて一晩インキュベートした後、1%ブロックエース(DSファーマバイオメディカル)により、ウェルを室温にて1時間ブロッキングした。0.05% Tween20/PBS(Thermo SCIENTIFIC)で3回洗浄した後、ウェルにマウス、ラット、サルおよびヒトEphA4細胞外領域-SEAP-Hisタンパク質(最終濃度1nM)を播種し、室温にて1時間インキュベートした。3回洗浄した後、ウェルにヒトIgG溶液(100μg/mL、三菱ウェルファーマ)および抗体B(0、0.00013、0.00064、0.0032、0.016、0.08、0.4、2、10μg/mL)を添加し、室温にて1時間インキュベートした。西洋ワサビペルオキシダーゼ標識ロバ抗ヒトIgG抗体(Jackson ImmunoResearch Laboratories)を加え、室温にて1時間インキュベートした。3回洗浄した後、ウェルにTMBZ(3,3’,5,5’-テトラメチルベンジジン、Sigma)溶液を加え、適度な発色を確認したらウェルに等量の反応停止溶液(1N H2SO4、和光純薬)を加え、マイクロプレートリーダー(PerkinElmer)により450nmの吸光度を読み取った。
実施例1で得た抗体Bについて、各種ヒトEphA4内ドメインとの結合活性の評価は、以下の工程に従って行った。
ウサギ抗6―His抗体(Bethyl Laboratories)を、96ウェルプレート(Nunc)のウェル上にコートした。4℃にて一晩インキュベートした後、1%ブロックエース(DSファーマバイオメディカル)により、ウェルを室温にて1時間ブロッキングした。0.02% Tween20/PBS(ナカライテスク)で2回洗浄した後、ウェルにヒトEphA4細胞外領域-MBP-Hisタンパク質、ヒトEphA4リガンド結合ドメイン-MBP-Hisタンパク質、ヒトEphA4フィブロネクチンIII型ドメイン1-MBP-Hisタンパク質、およびヒトEphA4フィブロネクチンIII型ドメイン2-MBP-Hisタンパク質(最終濃度10nM)を播種し、室温にて1時間インキュベートした。3回洗浄した後、ウェルに抗体B(最終濃度10nM)を添加し、室温にて1時間インキュベートした。西洋ワサビペルオキシダーゼ標識ウサギ抗ヒトIgG Fcγフラグメント抗体(Jackson ImmunoResearch Laboratories)を加え、室温にて1時間インキュベートした。5回洗浄した後、ウェルにTMB(KPL)溶液を加え、適度な発色を確認したらウェルに等量の反応停止溶液(2N H2SO4、和光純薬)を加え、マイクロプレートリーダー(PerkinElmer)により450nmおよび650nmの吸光度を読み取った。
ラット海馬ニューロンの調製は、参考例1の(B)に記載されるように行った。ラット海馬ニューロンにNucleofector(Lonza)を用いてEGFP遺伝子を導入し、ポリLリジンをコートしたカバーガラス(松浪硝子工業)を入れた24ウェルプレート(Falcon)に播種した。
実施例1で得た抗体Bについて、ヒトEphA4に対する切断促進活性の評価は、以下の工程に従って行った。
ラット海馬ニューロンの調製は、参考例1の(B)に記載されるように行った。ラット海馬ニューロンにNucleofector(Lonza)を用いてヒトEphA4-HAタンパク質発現ベクターを導入し、ポリLリジンをコートした96ウェルディッシュ(Falcon)に播種した。播種したラット海馬ニューロンに、抗体B(6.7、20、67nM)およびγセクレターゼ阻害薬であるCompoundE(50nM、Enzo Life Sciences)を処置して約24時間後にPBS(和光純薬)で洗浄して、SDS sample buffer(Laemmliサンプルバッファー(バイオ・ラッド)、5% 2-メルカプトエタノール(バイオ・ラッド))を加えて細胞を回収し、5分間煮沸した。このサンプルを用いてSDS-PAGEを行い、ラット抗HAモノクローナル抗体(Roche)を用いたウェスタンブロッティングを行い、バンド強度を定量化し、EphA4C末端フラグメント/全長EphA4の値を算出した。
ラット海馬ニューロンの調製は、参考例1の(B)に記載されるように行った。一部のラット海馬ニューロンにNucleofector(Lonza)を用いてEGFP遺伝子を導入し、ポリLリジンをコートしたカバーガラス(松浪硝子工業)を入れた24ウェルプレート(Falcon)に播種した。
(A)ヒトiPS細胞の維持培養
ヒトiPS細胞の維持培養は、以下の工程に従って行った。液体窒素でStem cell banker(Takara)にて凍結保存されたヒトiPS細胞(201B7)を液体窒素気層から取り出し、予め37℃に加温しておいたヒトiPS細胞培養培地(Essential 8、Thermofisher scientific)5mLに懸濁、融解した。15mLコニカルチューブ(Thermofisher scientific)に細胞懸濁液を回収し、1000rpm、5分、室温で遠心後、上清を除き、新たな培地に懸濁後、予め0.3μg/cm2 iMatrix-511(Nippi)でコーティングを行ったφ60mm細胞培養ディッシュ(Corning)に播種し、10μM Y-27632(WAKO)を添加した後、CO2インキュベーター内(37℃、5%CO2)で培養を行った。毎日、培地交換を行い、サブコンフルエントに達した時点で継代培養を行うことでヒトiPS細胞の維持培養を行った。継代培養は以下のように実施した。サブコンフルエントの状態のヒトiPS細胞の培養培地をアスピレートし、2mLのPBS(WAKO)で洗浄後、Accutase(Nacalai Tesque)1mLを添加してCO2インキュベーター内(37℃、5%CO2)で5分間インキュベートした。10μM Y-27632を含む4mLのヒトiPS細胞培養培地で懸濁することによってヒトiPS細胞を単細胞に解離し、その後15mLのコニカルチューブに回収した。1000rpm、5分、室温で遠心を行い、上清をアスピレートした後、ヒトiPS細胞を10μM Y-27632を含む1mLのヒトiPS細胞培養培地に懸濁した。細胞数を計測し、2×105個のヒトiPS細胞を4mLのヒトiPS細胞培養培地に懸濁した後、0.3μg/cm2 iMatrix-511でコーティングしたφ60mm細胞培養ディッシュに播種し、CO2インキュベーター内(37℃、5%CO2)で培養を行った。実験には、継代培養を1回以上実施したヒトiPS細胞を用いた。
マウス新生仔からのアストロサイトの樹立および維持培養は、以下の工程に従って行った。生後2日齢の野生型マウス新生仔(C57BL/6JJmsSlc(日本エスエルシー))および野生型マウスと変異ヒトSOD1(G93A)Tg-(B6.Cg-Tg(SOD1 G93A)1Gur/J(Jackson Laboratories))マウスとの交雑マウスの新生仔をイソフルラン(インターベット)吸入麻酔下で断頭により安楽死させた後、大脳皮質を単離し、0.25%トリプシン‐EDTA(Thermofisher Scientific)で37℃、15分処理により分散した。酵素処理後、10%FBS(Thermofisher Scientific)および1%ペニシリン ストレプトマイシン(Nacalai Tesque)含有Dulbecco’s Modified Eagle Medium(Thermofisher Scientific)(10%FBS-DMEM)4mLによって希釈し、酵素消化を停止させた。その後、セルストレーナー(Corning)により、単一細胞以外の不純物をフィルトレーションし、1500rpmで5分遠心した。上清をアスピレートし、細胞を新しい10%FBS-DMEM 4mLに希釈して、個体毎にφ60mm細胞培養ディッシュに播種、37℃にて培養した。播種2日後に培地をアスピレートし、新たな10%FBS-DMEM 4mLを細胞に加え培地交換を行った。コンフルエントに達した後、継代培養を実施した。マウス新生仔由来アストロサイトの継代培養は以下のように実施した。φ60mm細胞培養ディッシュ上でコンフルエントに達したアストロサイトの10%FBS-DMEMをアスピレートした後、PBS(WAKO)2mLで洗浄し、0.25%トリプシン‐EDTA 1mLを加えてCO2インキュベーター内(37℃、5%CO2)で3分インキュベートした。10%FBS-DMEM 3mLで懸濁することによりアストロサイトを単細胞に解離し、その後15mLコニカルチューブに回収した。1500rpm、3分、室温で遠心し、上清をアスピレートした後、細胞に新たな10%FBS-DMEM 8mLを加え、φ100mm細胞培養ディッシュに播種した(継代1)。継代培養は細胞がコンフルエントに達した際に上記と同様の方法で実施した。なお、φ100mm細胞培養ディッシュで培養したアストロサイトの継代培養時には、4mLのPBS、および2mLの0.25%トリプシン‐EDTAを使用した。また、継代培養時に細胞懸濁液の一部を回収し、変異ヒトSOD1(G93A)のジェノタイピングに供した。継代培養を合計3回実施したアストロサイトをCell banker(日本全薬工業)に希釈して試験供試まで-80℃で凍結保存した。試験供試に際しては、凍結保存した細胞懸濁液をそれぞれ恒温槽内で融解した後、予め37℃に加温した10%FBS-DMEMで希釈した。各細胞懸濁液を遠心後(1500rpm、3分、室温)、上清を除き、新たな培地に懸濁後、8ウェルチャンバー(ibidi)に播種し、CO2インキュベーター内(37℃、5%CO2)で維持培養を行った。
In vitro ALSモデルにおけるヒトiPS細胞由来運動ニューロン保護効果の評価は、以下の工程に従って行った。上記(A)の継代培養と同様の方法でヒトiPS細胞の単細胞懸濁液を得たのち、1000rpm、5分、室温で遠心を行い、上清をアスピレートした。ヒトiPS細胞をDFK20培地(20%Knockout serum replacement(KSR、Thermofisher Scientific)、1%Non-essential amino acid(NEAA、Thermofishere Scientific)、1%GlutaMAX-I Supplement(Thermofisher scientific)、100units/mL ペニシリン-100μg/mLストレプトマイシン(Nacalai Tesque)、100μM β-メルカプトエタノール(Thermofisher Scientific)を含むDMEM/F12(Thermofisher Scientific))で懸濁した後、細胞数を計測した。3×105個のヒトiPS細胞に対して10μM SB431542(Sigma)、100nM LDN193189(Sigma)、3μM CHIR99021(Cayman Chemical)、10μM Y-27632を含むDFK20培地を2mLで懸濁し、低接着性6ウェル細胞培養プレート(Corning)の1ウェルに播種し、CO2インキュベーター内(37℃、5%CO2)で培養した。培養3日目、ヒトiPS細胞分化細胞塊(SFEBs)を培地ごと15mLコニカルチューブに回収し、300rpm、2分、常温で遠心することで、細胞塊を沈殿させた。この上清をアスピレートし、SFEBsを10μM SB431542、100nM LDN193189、3μM CHIR99021(Cayman)、5μM Y-27632、1μM Retinoic Acid(Sigma)を含むDFK20培地で緩やかに懸濁し、元のウェルに戻すことで培地交換を行った。培養5日目も同様の方法で培地交換を実施した。ただし、Y-27632の濃度は2.5μMにして培地交換を実施した(その他の化合物は培養3日目と同じ)。培養7日目、SFEBsを培地ごと15mLコニカルチューブに回収し、10分常温で静置することで、SFEBsを沈殿させた。この上清をアスピレートし、1μM Retinoic Acid、1μM Purmorphamine(Myltenyi Biotech)を含む、3mLのDFK5培地(5%KSR、1%NEAA、1%GlutaMAX-I Supplement、100units/mL ペニシリン-100μg/mLストレプトマイシン、100μM β-メルカプトエタノールを含むDMEM/F12)でSFEBsを懸濁して元のウェルに戻し、CO2インキュベーター内(37℃、5%CO2)で培養した。その後、2-3日毎に、培養7日目と同じ工程で培地交換を行い、ヒトiPS細胞を運動ニューロンへと分化誘導した。培養33日目に、SFEBsを培地ごと15mLコニカルチューブに回収し、5分常温で静置することで、SFEBsを沈殿させた。上清をアスピレートし、10μM Y-27632を含む2mLのAccutaseを加えて、37℃恒温水槽で10分インキュベートした。その後、P1000ピペットで、30回ピペッティングして細胞塊を分散させたのち、10μM Y-27632を含む10mLのDFK5培地で酵素反応を停止させた。細胞懸濁液を新たな15mLコニカルチューブに回収し、1000rpm、5分、室温で遠心し、上清をアスピレートした。10μM Y-27632を含むDFK5培地で細胞を再懸濁した後、セルストレーナー(Corning)でフィルトレーションを行い、その後、細胞数を計測した。共培養培地(2%B27 Supplement(Thermofisher Scientific)、10μM Y-27632、1%GlutaMax-I Supplement、100units/mL ペニシリン-100μg/mL ストレプトマイシンを含むNeurobasal培地(Thermofisher Scientific)で細胞を5×105個/mLの懸濁液に調製し、コントロール群、vehicle添加群および薬物処置群に分けた。薬物の希釈は共培養培地を用いた。Vehicle(共培養培地)および薬物である抗体Bをそれぞれの群に添加した後、予めマウス由来野生型アストロサイトまたは変異ヒトSOD1(G93A)発現アストロサイトを8×104個/ウェルで播種した8ウェルチャンバーに200μL/ウェルで播種し、アストロサイトと運動ニューロンの共培養細胞として評価に使用した。野生型アストロサイトと運動ニューロンとの共培養で観察される運動ニューロン数をコントロールとした。Vehicle添加群および薬物処置群では、変異ヒトSOD1(G93A)発現アストロサイトと運動ニューロンとの共培養を行い、条件をvehicle添加(1%共培養培地)、抗体B(10、30、100nmol/L)とした。各条件でCO2インキュベーター内(37℃、5%CO2)において2日間培養後、抗ISL1抗体(Abcam)および抗Human Nuclear Antigen(HNA)抗体(Millipore)を用いて運動神経細胞を免疫細胞化学的に染色した。1ウェルあたりのISL1/HNA共陽性細胞を生存運動ニューロンとして計数し、運動ニューロン生存率はコントロールに対する%として算出した。なお、図22に評価系の工程を示す簡単な模式図を示す。
Claims (15)
- 抗EphA4抗体を含む、筋萎縮性側索硬化症(ALS)を治療するための医薬組成物であって、
前記抗EphA4抗体は、
(a)配列番号44に示すアミノ酸配列からなる重鎖CDR1;
(b)配列番号27に示すアミノ酸配列からなる重鎖CDR2;および
(c)配列番号28に示すアミノ酸配列からなる重鎖CDR3を含む重鎖;および
(d)配列番号29に示すアミノ酸配列からなる軽鎖CDR1;
(e)配列番号30に示すアミノ酸配列からなる軽鎖CDR2;および
(f)配列番号31に示すアミノ酸配列からなる軽鎖CDR3を含む軽鎖
を含む、
医薬組成物。 - 請求項1に記載の医薬組成物であって、
前記抗EphA4抗体は、ヒト化されている、
医薬組成物。 - 請求項1または2に記載の医薬組成物であって、
前記抗EphA4抗体は、EphA4に特異的に結合し、EphA4の切断を促進する、
医薬組成物。 - 請求項1~3のいずれか1項に記載の医薬組成物であって、
前記抗EphA4抗体は、EphA4に特異的に結合し、EphA4とephrinとの結合を阻害する、
医薬組成物。 - 請求項1~4のいずれか1項に記載の医薬組成物であって、
前記重鎖は配列番号45に示すアミノ酸配列からなる可変領域を含み、
前記軽鎖は配列番号46に示すアミノ酸配列からなる可変領域を含む、
医薬組成物。 - 請求項1~5のいずれか1項に記載の医薬組成物であって、
前記重鎖の定常領域および前記軽鎖の定常領域がヒト抗体由来のアミノ酸配列を含む、
医薬組成物。 - 請求項6に記載の医薬組成物であって、
前記重鎖の定常領域はヒトIgGの定常領域である、
医薬組成物。 - 請求項7に記載の医薬組成物であって、
前記ヒトIgGの定常領域はヒトIgG2の定常領域である、
医薬組成物。 - 請求項8に記載の医薬組成物であって、
前記ヒトIgG2の定常領域は、配列番号47に示すアミノ酸配列を含む、
医薬組成物。 - 請求項6~9のいずれか1項に記載の医薬組成物であって、
前記軽鎖の定常領域はヒトIgκの定常領域である、
医薬組成物。 - 請求項10に記載の医薬組成物であって、
前記ヒトIgκの定常領域は、配列番号48に示すアミノ酸配列を含む、
医薬組成物。 - 抗EphA4抗体を含む、筋萎縮性側索硬化症(ALS)を治療するための医薬組成物であって、
前記抗EphA4抗体は、重鎖および軽鎖を含み、
前記重鎖は、配列番号59に示すアミノ酸配列を含み、
前記軽鎖は、配列番号60に示すアミノ酸配列を含み、
前記重鎖のC末端リシンが欠失されていてもよい、
医薬組成物。 - 請求項12に記載の医薬組成物であって、
前記重鎖のC末端リシンが欠失されている、
医薬組成物。 - 筋萎縮性側索硬化症(ALS)治療用の医薬組成物を製造するための抗EphA4抗体の使用であって、
前記抗EphA4抗体は、
(a)配列番号44に示すアミノ酸配列からなる重鎖CDR1;
(b)配列番号27に示すアミノ酸配列からなる重鎖CDR2;および
(c)配列番号28に示すアミノ酸配列からなる重鎖CDR3を含む重鎖;および
(d)配列番号29に示すアミノ酸配列からなる軽鎖CDR1;
(e)配列番号30に示すアミノ酸配列からなる軽鎖CDR2;および
(f)配列番号31に示すアミノ酸配列からなる軽鎖CDR3を含む軽鎖
を含む、
抗EphA4抗体の使用。 - 請求項14に記載の抗EphA4抗体の使用であって、
前記重鎖は配列番号45に示すアミノ酸配列からなる可変領域を含み、
前記軽鎖は配列番号46に示すアミノ酸配列からなる可変領域を含む、
抗EphA4抗体の使用。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/029,540 US20240010735A1 (en) | 2020-12-24 | 2021-12-22 | Therapeutic pharmaceutical composition for amyotrophic lateral sclerosis |
MX2023004848A MX2023004848A (es) | 2020-12-24 | 2021-12-22 | Composicion farmaceutica terapeutica para tratar la esclerosis lateral amiotrofica. |
CA3195085A CA3195085A1 (en) | 2020-12-24 | 2021-12-22 | Therapeutic pharmaceutical composition for amyotrophic lateral sclerosis |
JP2022571541A JPWO2022138707A1 (ja) | 2020-12-24 | 2021-12-22 | |
CN202180078579.1A CN116710133A (zh) | 2020-12-24 | 2021-12-22 | 肌萎缩侧索硬化的治疗用药物组合物 |
EP21910847.9A EP4268847A1 (en) | 2020-12-24 | 2021-12-22 | Pharmaceutical composition for treatment of amyotrophic lateral sclerosis |
KR1020237015047A KR20230124547A (ko) | 2020-12-24 | 2021-12-22 | 근위축성 측삭 경화증에 대한 치료적 약학 조성물 |
AU2021410290A AU2021410290A1 (en) | 2020-12-24 | 2021-12-22 | Pharmaceutical composition for treatment of amyotrophic lateral sclerosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-214739 | 2020-12-24 | ||
JP2020214739 | 2020-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022138707A1 true WO2022138707A1 (ja) | 2022-06-30 |
Family
ID=82159764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/047532 WO2022138707A1 (ja) | 2020-12-24 | 2021-12-22 | 筋萎縮性側索硬化症の治療用医薬組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20240010735A1 (ja) |
EP (1) | EP4268847A1 (ja) |
JP (1) | JPWO2022138707A1 (ja) |
KR (1) | KR20230124547A (ja) |
CN (1) | CN116710133A (ja) |
AU (1) | AU2021410290A1 (ja) |
CA (1) | CA3195085A1 (ja) |
MX (1) | MX2023004848A (ja) |
TW (1) | TW202241503A (ja) |
WO (1) | WO2022138707A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008150010A1 (ja) * | 2007-06-08 | 2008-12-11 | Eisai R & D Management Co., Ltd. | γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法 |
US20100297697A1 (en) | 2007-08-29 | 2010-11-25 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Methods for increasing protein titers |
WO2012081502A1 (ja) * | 2010-12-17 | 2012-06-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法 |
WO2012156351A1 (en) | 2011-05-13 | 2012-11-22 | Vib Vzw | Epha4 is a disease modifier in motor neuron disease |
WO2016019280A1 (en) | 2014-07-31 | 2016-02-04 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human monoclonal antibodies against epha4 and their use |
WO2017043466A1 (ja) | 2015-09-08 | 2017-03-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗EphA4抗体 |
WO2021002312A1 (ja) * | 2019-07-01 | 2021-01-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗EphA4抗体 |
-
2021
- 2021-12-22 EP EP21910847.9A patent/EP4268847A1/en active Pending
- 2021-12-22 KR KR1020237015047A patent/KR20230124547A/ko unknown
- 2021-12-22 CN CN202180078579.1A patent/CN116710133A/zh active Pending
- 2021-12-22 AU AU2021410290A patent/AU2021410290A1/en active Pending
- 2021-12-22 US US18/029,540 patent/US20240010735A1/en active Pending
- 2021-12-22 WO PCT/JP2021/047532 patent/WO2022138707A1/ja active Application Filing
- 2021-12-22 JP JP2022571541A patent/JPWO2022138707A1/ja active Pending
- 2021-12-22 TW TW110148161A patent/TW202241503A/zh unknown
- 2021-12-22 CA CA3195085A patent/CA3195085A1/en active Pending
- 2021-12-22 MX MX2023004848A patent/MX2023004848A/es unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008150010A1 (ja) * | 2007-06-08 | 2008-12-11 | Eisai R & D Management Co., Ltd. | γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法 |
US20100297697A1 (en) | 2007-08-29 | 2010-11-25 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Methods for increasing protein titers |
WO2012081502A1 (ja) * | 2010-12-17 | 2012-06-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法 |
WO2012156351A1 (en) | 2011-05-13 | 2012-11-22 | Vib Vzw | Epha4 is a disease modifier in motor neuron disease |
WO2016019280A1 (en) | 2014-07-31 | 2016-02-04 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human monoclonal antibodies against epha4 and their use |
WO2017043466A1 (ja) | 2015-09-08 | 2017-03-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗EphA4抗体 |
WO2021002312A1 (ja) * | 2019-07-01 | 2021-01-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗EphA4抗体 |
Non-Patent Citations (21)
Title |
---|
"Genbank", Database accession no. NM_001260870.1 |
ACTA CRYST, vol. 67, 2011, pages 235 - 242 |
AL-LAZIKANI ET AL., J. MOLEC. BIOL., vol. 273, 1997, pages 927 - 948 |
CARTER ET AL., PROC. NATL. ACAD. SET USA, vol. 89, 1992, pages 4285 - 4289 |
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
EMSLEY P ET AL., ACTA CRYST, vol. 60, 2004, pages 2126 - 2132 |
GOLDSHMIT ET AL., PLOS ONE, vol. 6, 2011, pages e24636 |
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH |
KONTERMANN, MABS, vol. 4, 2012, pages 182 - 97 |
KONTERMANNDUBEL: "Springer Lab Manual", 2001, article "Antibody Engineering" |
LIU H ET AL., MABS, vol. 6, no. 5, September 2014 (2014-09-01), pages 1145 - 1154 |
MCCOY A. J. ET AL., J. APPL. CRYST., vol. 40, 2007, pages 658 - 674 |
MURSHUDOV G.N., ACTA CRYST, vol. 53, 1997, pages 240 - 255 |
PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623 - 2632 |
QIN H ET AL., J. BIOL. CHEM., vol. 283, 2008, pages 29473 - 29484 |
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327 |
SPANEVELLO ET AL., JOURNAL OF NEUROTRAUMA, vol. 30, 2013, pages 1023 - 1034 |
TSURUSHITA ET AL., METHODS, vol. 36, 2005, pages 69 - 83 |
VAN HOECKE ET AL., NATURE MEDICINE, vol. 18, 2012, pages 1418 - 1422 |
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536 |
Also Published As
Publication number | Publication date |
---|---|
US20240010735A1 (en) | 2024-01-11 |
CA3195085A1 (en) | 2022-06-30 |
AU2021410290A1 (en) | 2023-06-29 |
MX2023004848A (es) | 2023-05-10 |
JPWO2022138707A1 (ja) | 2022-06-30 |
TW202241503A (zh) | 2022-11-01 |
EP4268847A1 (en) | 2023-11-01 |
KR20230124547A (ko) | 2023-08-25 |
CN116710133A (zh) | 2023-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107847595B (zh) | 特异性针对过度磷酸化τ蛋白的抗体及其使用方法 | |
JP6770153B2 (ja) | 抗EphA4抗体 | |
JP7072114B2 (ja) | 抗EphA4抗体 | |
WO2022138707A1 (ja) | 筋萎縮性側索硬化症の治療用医薬組成物 | |
WO2022138708A1 (ja) | 抗EphA4抗体 | |
RU2816371C2 (ru) | АНТИТЕЛО К EphA4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21910847 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3195085 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022571541 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18029540 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180078579.1 Country of ref document: CN |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023011278 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021410290 Country of ref document: AU Date of ref document: 20211222 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023115025 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 112023011278 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230607 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021910847 Country of ref document: EP Effective date: 20230724 |